



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>6</sup> : <b>A61K 38/00, 45/05, 38/19, 39/395</b></p>	<p><b>A1</b></p>	<p>(11) International Publication Number: <b>WO 97/46249</b> (43) International Publication Date: 11 December 1997 (11.12.97)</p>
<p>(21) International Application Number: PCT/US97/09684 (22) International Filing Date: 4 June 1997 (04.06.97) (30) Priority Data: 60/018,972 4 June 1996 (04.06.96) US (71) Applicant (for all designated States except US): THE SCRIPPS RESEARCH INSTITUTE [US/US]; 10666 North Torrey Pines Road, Mail Drop TPC-8, La Jolla, CA 92037 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): FENG, Lili [CN/US]; 7430 Mason Heights Lane, San Diego, CA 92126 (US). CHEN, Sizhong [CN/US]; 7896 Camino Kiosco, San Diego, CA 92122 (US). XIA, Yiyang [CN/US]; 7430 Mason Heights Lane, San Diego, CA 92126 (US). (74) Agents: OLSON, Arne, M.; Olson &amp; Hierl, Ltd., 36th floor, 20 North Wacker Drive, Chicago, IL 60606 (US) et al.</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i></p>
<p>(54) Title: DIAGNOSTIC AND THERAPEUTIC METHODS RELATED TO REGULATING ENERGY MOBILIZATION WITH OB PROTEIN AND OB ANTIBODIES (57) Abstract  Compositions comprising OB-R agonists and methods of treatment for conditions such as systemic inflammatory response syndrome are provided. One suitable OB-R agonist ligand is recombinant human OB protein, also known as leptin. Also provided are methods and compositions for the treatment of obesity and OB resistance. Assay methods and kits relating to these conditions are also included.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

**DIAGNOSTIC AND THERAPEUTIC METHODS RELATED TO  
REGULATING ENERGY MOBILIZATION WITH  
OB PROTEIN AND OB ANTIBODIES**

5     Reference to Related Application

          This application claims the benefit of U.S. Provisional Application S.N. 60/018,972, filed June 4, 1996, which is incorporated by reference, as are all references cited herein.

Governmental Rights

10           This invention was made with governmental support from the United States Government, National Institutes of Health, Grant DK20043; the United States Government has certain rights in the invention.

Background of the Invention

          The *obese* gene in human, rat and mouse encodes a protein  
15     hormone having an open reading frame 167 amino acid residues in length, called leptin, also known as OB protein or the *ob* gene product. Removal of the signal sequence yields a mature secreted 16 kilodalton protein that is 146 amino acid residues in length.

          OB protein is produced primarily by adipocytes of white adipose  
20     tissue (WAT). OB protein is secreted directly into the extracellular space and travels through the blood stream. OB protein affects the cells of its target organs by binding to the OB receptor protein, OB-R, that is found on the extracellular surface of the plasma membrane of target cells. Binding of OB protein to OB-R activates the intracellular second messenger cascade of the JAK-STAT system,  
25     which is characteristic of activation of cytokine type I receptors.

          OB protein is produced in adipocytes in proportion to the mass of stored fat, thereby providing a hormone signal for a lipostatic feedback circuit, which is mediated by the OB receptor. While OB proteins of different species show a close similarity in their sequences, the sequences of OB proteins are not  
30     closely similar to other types of proteins. For example, the human *ob* gene

sequence and its mouse homologue (85% sequence identity) have been reported to have no sequence similarity to other proteins of known structure (DiFrancesco, V., et al., Protein Topology Recognition from Secondary Structure Sequences: Application of the Hidden Markov Models to Alpha Class Proteins, J. Mol. Biol. 267: 446-463 (1997) at page 457).

Although OB protein is composed of a single peptide chain, an intrachain disulfide bond between cysteine 96 and cysteine 146 is required both to stabilize the conformation of the molecule and to confer *in vivo* biological activity (Rock, F.L., et al., The Leptin Haemopoietic Cytokine Fold is Stabilized by an Intrachain Disulfide Bond, Horm. Metab. Res. 28: 649-652 (1996)). It is believed that the special geometry of the A and D major helices must be maintained in order to dock to a conserved receptor trough in the receptor molecule, a requirement that produces structural similarity between OB proteins and cytokines in the face of negligible sequence conservation (*Id.* at 651.).

One accepted and successful animal model of human obesity is the genetically obese mouse bearing the recessive *obese* mutation (*ob/ob*). The mouse model reproduces not only the human obesity condition, but also develops non-insulin dependent diabetes mellitus (NIDDM, also known as type II diabetes mellitus). Homologous *obese* genes have been described in mouse, rat and human.

The mouse is also a widely accepted and successful model of sepsis, septic shock and systemic inflammatory response syndrome (SIRS), a term which describes the clinical syndrome of sepsis without regard to its cause. Simple models, involving a large bolus dose of lipopolysaccharide (LPS) administered to mice and using mortality as the primary outcome variable, are well suited for preliminary pharmacological studies of new drugs or other therapeutic agents (Fink, M.P. & Heard, S.O., Laboratory Models of Sepsis and Septic Shock, J. Surg. Res. 49: 186-196, 1990, at 188-189).

Both the *ob* gene (Zhang, Y., et al., Positional cloning of the mouse *obese* gene and its human homologue, Nature 372: 425-432 (1994);

accession No. U18812, SEQ ID NO. 1) and its receptor (Tartaglia, L.A., et al., Identification and expression cloning of a Leptin Receptor, Cell 83: 1263-1271 (1995); Chen, H., et al., Evidence that the Diabetes Gene Encodes the Leptin Receptor: Identification of a Mutation in the Leptin Receptor Gene in *db/db* Mice Cell 84: 491-495 (1996); accession No. U46135, SEQ ID NO. 2) have been cloned. Shorter versions of the OB receptor, termed the OB-Ra, OB-Rc and OB-Re forms, are produced by alternative splicing of the OB-R mRNA (Lee, G.-H., et al. Nature 379: 632-635 (1996)). The full length OB receptor is called the OB-Rb form.

Neural activity in specific regions of the central nervous system (CNS), such as the hypothalamus, controls processes related to food intake and energy expenditure. The cloning of the OB protein gene and the OB receptor gene and the localization of OB receptor expression in the hypothalamus has provided supporting evidence for this view as well as suggesting possible mechanisms for relating food intake to stored fat reserves. The OB protein is produced by adipocytes in proportion to the mass of stored fat and, hence, it acts as the signal to a lipostat control circuit. This lipostat signal is transduced at the target cells by the OB receptor, OB-R, in the CNS, resulting changes in neural activity that regulate both food intake and metabolic rate.

Metabolic derangement is an important characteristic of the host response to critical illness called the acute phase response that characterizes conditions such as sepsis and septic shock (Kushner, I. Ann. N.Y. Acad. Sci. 389: 39-48 (1982)). Hypothermia is a metabolic response that may be pertinent clinical prognostic factor in systemic inflammatory response syndrome in humans (Brivet, F., et al. Crit. Care Med. 22: 533-534 (1994)).

There is a need for at least one disease marker for systemic inflammatory response syndrome (SIRS) and related conditions. Hereinafter, the term SIRS is used to denote sepsis, septic shock, sepsis syndrome, and related conditions. Disease markers have numerous functions. In this case, a marker for SIRS would be useful for predicting the development of SIRS, identifying patients

with SIRS, predicting outcome, aiding timing and targeting of therapeutic interventions, and determining the pathogenesis of SIRS in patients (Parsons, P.E. & Moss, M. Early Detection and Markers of Sepsis, Clinics in Chest Medicine 17:199-212 (1996)).

5     Summary of the Invention

Embodiments of the present invention include compositions and methods for treating a patient having a condition in which regulating energy metabolism during a systemic inflammatory response is desired, comprising administering a composition having a physiologically effective amount of at least  
10     one OB-R agonist ligand. Suitable OB-R agonist ligands include recombinant OB protein, peptide conformational analogs of human OB protein comprising conservative substitutions of amino acid residues and OB-related peptides. A preferred OB-R agonist ligand is recombinant human OB protein.

In another therapeutic embodiment, the beneficial aspects of OB-R  
15     agonist ligand administration are facilitated by a coordinated increase in the number of OB receptors (OB-R) produced by the administration of agents that OB-R expression inducers. Suitable OB-R expression inducers include lipopolysaccharide (LPS) and cytokines. Preferred cytokines are interleukin-1 $\alpha$  (IL-1 $\alpha$ ), interleukin-1 $\beta$  (IL-1 $\beta$ ), tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) and interleukin  
20     6 (IL-6). Particularly preferred cytokines are IL-6 and IL-1 $\beta$ .

In a further therapeutic embodiment, antibodies to OB protein are used as agents capable of blocking the effects of OB receptor activation, especially fat mobilization and increased energy utilization. Suitable antibodies to OB proteins may be polyclonal or monoclonal. Suitable antibodies comprise  
25     immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antibody combining site or paratope. Exemplary antibody molecules are intact immunoglobulin molecules, substantially intact immunoglobulin molecules and those portions of an immunoglobulin molecule that contain the paratope, including those portions  
30     known in the art as Fab, Fab' and F(ab')<sub>2</sub>. This embodiment is suitable for

treating metabolic derangement due to conditions such as anorexia, amenorrhea, cachexia and the like.

Antibodies to OB protein are also useful as an assay kit and method for detecting the level of OB protein in a patient. The level of OB protein in a patient is a disease marker that is useful for predicting the development of a condition, identifying patients with the condition, predicting outcome of the condition, aiding timing and targeting of therapeutic interventions, and determining the pathogenesis of the condition in patients. Conditions in which the level of OB protein is a useful marker are SIRS and related conditions such as sepsis and septic shock, as well as anorexia, amenorrhea, cachexia and the like.

#### Brief Summary of the Drawings

In the drawings:

Figure 1 is a representation of an autoradiogram showing the results of a ribonuclease (RNase) protection assay showing expression of total OB receptor (OB-R<sub>0</sub>) in lung, kidney and liver at 0, 4, 8 or 24 hours, or 2 (D<sub>2</sub>), 3 (D<sub>3</sub>) or 5 (D<sub>5</sub>) days after intravenous injection of 5 µg per gram of body weight as well as a dose-response study showing the relative effects on the liver the of injection of 0.05, 0.5 or 5 µg of LPS per gram of body weight;

Figure 2 is a representation of an autoradiogram showing of the results of a RNase protection assay showing expression of OB-Rb in normal liver (lane 1), and the LPS-treated liver at 24 hours (lane 2), and in the hypothalamus of normal control (lane 3) and *ob/ob* mice (lane 4), compared to OB-R<sub>(m)</sub> which represents the mixture of OB-R forms partially protected by the designated nucleotide probes;

Figure 3 is a representation of an autoradiogram showing the results of a RNase protection assay showing expression of OB-Rc in normal liver (lane 1), and the LPS-treated liver at 24 hours (lane 2), and in the hypothalamus of normal control (lane 3) and *ob/ob* mice (lane 4), compared to OB-R<sub>(m)</sub> which

represents the mixture of OB-R forms partially protected by the designated nucleotide probes;

Figure 4 is a representation of an autoradiogram showing the results of a RNase protection assay showing expression of OB-Re in normal liver (lane 1), and the LPS-treated liver at 24 hours (lane 2), and in the hypothalamus of normal control (lane 3) and *ob/ob* mice (lane 4), compared to OB-R<sub>(m)</sub> which represents the mixture of OB-R forms partially protected by the designated nucleotide probes;

Figure 5 is a representation of an autoradiogram showing the results of a RNase protection assay showing OB-R expression in mouse liver 24 hours after IL-6 (2.5  $\mu$ g per mouse), TNF- $\alpha$  (10  $\mu$ g per mouse) and IL-1 $\beta$  (5  $\mu$ g per mouse) injection;

Figure 6 is a representation of an autoradiogram showing the results of a RNase protection assay showing OB-R mRNA levels in brain cortex, hypothalamus, and brain stem at various times after LPS injection (5  $\mu$ g per gram of body weight);

Figure 7 is a representation of an autoradiogram showing the results of a RNase protection assay showing OB mRNA expression in the adrenal gland (Adr) and white adipose tissue (WAT) at various times after LPS injection (5  $\mu$ g per gram of body weight);

Figure 8 is a graphical representation of the construction scheme for the vector pETM1 from a commercially available vector;

Figure 9 is a graphical representation of the weight gain induced by anti-OB antiserum injection in C57BL/6 mice which were given daily injections of anti-OB antiserum (antiOB) or preimmune rabbit sera (control), and whose body weight was measured 12 hours later, where data are expressed as mean  $\pm$  standard error of the mean (S.E.M), N=8;

Figure 10 is a graphical representation of the time course of the survival of mice that had received a LPS injection (6  $\mu$ g per gram of body weight) after pretreatment with either anti-OB protein antiserum (anti-OB,



N=16), preimmune rabbit serum (control, N=16), or one of three other unrelated rabbit antisera (anti-X, N=9: 3 treated with each antiserum);

Figure 11 is a graphical representation of the time course of the survival of mice that were treated with OB protein (mOB, N=16) or vehicle (control, N=16) after a LPS injection (10  $\mu$ g per gram of body weight);

Figure 12 is a graphical representation of the time course of the change in body temperature of mice that had received a LPS injection (6  $\mu$ g per gram of body weight) after pretreatment with either anti-OB protein antiserum (anti-OB, N=16, except at \* where N < 16 due to mortality) or preimmune rabbit serum (control, N=16), data expressed as mean  $\pm$  S.E.M.;

Figure 13 is a graphical representation of the time course of the change in body temperature of mice that were treated with OB protein (mOB, N=16) or vehicle (control, N=16, except at \* where N < 16 due to mortality) after a LPS injection (10  $\mu$ g per gram of body weight), data expressed as mean  $\pm$  S.E.M.;

Figure 14 is a graphical representation of the time course of the change in body weight (percent of initial body weight) of mice that had received a LPS injection (6  $\mu$ g per gram of body weight) after pretreatment with either anti-OB protein antiserum (anti-OB, N=16) or preimmune rabbit serum (control, N=16, except at \* where N < 16 due to mortality), data expressed as mean  $\pm$  S.E.M.;

Figure 15 is a graphical representation of the time course of the change in body weight (percent of initial body weight) of mice that were treated with OB protein (mOB, N=16) or vehicle (control, N=16, except at \* where N < 16 due to mortality) after a LPS injection (10  $\mu$ g per gram of body weight), data expressed as mean  $\pm$  S.E.M.; and

Figure 16 is a representation of an autoradiogram showing the results of a RNase protection assay showing the expression of iNOS, IL-1 $\alpha$ , IL-1 $\beta$ , and TNF- $\alpha$  mRNAs in mouse.

### Detailed Description of the Preferred Embodiments

It has been found that substances that initiate or mediate SIRS, for example, LPS and several cytokines, induce the increased expression of OB-R in liver and other peripheral tissues. Thus, occupancy and activation of OB-R by an agonist ligand such as recombinant OB protein, OB-related peptides or peptide conformational analog of human OB protein comprising conservative substitutions of amino acid residues serves as a protective homeostatic mechanism in systemic inflammatory response syndrome conditions such as endotoxic shock, sepsis and septic shock. A preferred OB-R agonist ligand is recombinant OB protein.

Suitable therapeutic human doses of recombinant OB protein are from about 1 micrograms per kilogram body weight to about 50 microgram per kilogram body weight. One preferable therapeutic human dose is about 10 micrograms per kilogram body weight.

While the regulation of energy homeostasis is essentially a function of the CNS, food intake and the majority of the energy expenditure take place in peripheral organs such as the liver. It has been found that the OB protein and the OB receptor have a functional involvement in peripheral energy homeostasis. In general, critical illness and trauma can dramatically alter metabolism, with the expression of the OB receptor changing in response to pathological stress. The expression of OB-R in liver and other peripheral organs, but not in the central nervous system, has now been shown to be induced by endotoxic shock produced intravenous injection of cytokines, such as, IL-1 $\beta$ , TNF- $\alpha$  and IL-6, as well as cytokine inducing agents such as LPS, into mice, an accepted animal model of SIRS and related conditions. OB protein, antibodies to OB protein, and OB-R expression inducers are useful for the diagnosis and treatment of conditions such as sepsis, systemic inflammatory response syndrome, cachexia and anorexia.

The administration of recombinant mouse OB protein to mice following OB-R induction with a normally lethal dose of LPS conferred complete resistance to LPS, resulting in survival. The OB-treated mice maintained a higher body temperature and displayed dramatic weight loss in contrast to control

counterparts. In vivo administration of OB antisera, on the other hand, elicited the opposite effects by blocking OB-mediated processes, thereby stimulating post-prandial food intake leading to rapid weight gain. Co-administration of LPS with a second in vivo treatment with OB antisera, however, resulted in 100% mortality as compared to animals treated with control antisera.

OB protein, in mediating host responses to LPS-induced endotoxemia, exerts its protective effect primarily by initiating energy mobilization and heat production in critical conditions, the effect of which is proportional to the level of OB protein in the blood. By altering the levels of OB protein, the amount of energy mobilized to resist challenges induced by inflammatory agents is correspondingly altered, thereby effecting the ultimate inflammatory response.

Therefore, in view of the newly discovered physiological properties of OB protein and OB antibodies in regulating energy mobilization and consumption, the present invention describes both diagnostic and therapeutic methods relating to the use of recombinant human OB protein and antibodies thereto in modulating the effects of OB-R activation in vivo.

#### Diagnostic Applications

OB antibodies are useful for detecting the amount of OB present in sample taken from a patient. One preferred diagnostic embodiment is the use of OB antibodies for detecting the amount of OB present in a blood sample taken from a patient exhibiting a SIRS condition such as sepsis, septic shock, and the like. Such measurements of OB levels in vitro in blood sample by antibody detection is also indicated in various wasting conditions or syndromes associated with several disease states or syndromes, including anorexia, amenorrhea, cachexia, chronic inflammatory conditions, AIDS and AIDS-related conditions, as well as sepsis, septic shock, SIRS and the like. Alternatively, the determination of OB levels is useful in systemic inflammatory response syndromes (SIRS) that are characterized by an acute increase in inflammatory mediators, such as IL-1 $\beta$ , IL-6, TNF, LPS and the like. Such conditions are noted in preoperative patients

subject to fasting, in patients with acute injuries such as burns or trauma, in patients with SIRS, or with ongoing bacterial infections or those receiving TNF- $\alpha$  for treatment of tumors and in persons suffering from hypothermia.

While there is little sequence similarity between OB proteins and other molecules, the three-dimensional conformation of the OB protein molecule is analogous to that of several long-chain helical cytokines: four major alpha helix regions, A-D, connected by short loops and minor helical regions (Zhang, F., et al., Crystal Structure of the *obese* protein leptin-E100, Nature **387**: 206-209 (1997)).

As used herein, a conformational analog of OB protein is a molecule having substantially the same conformational characteristics of its three-dimensional structure that are required for activation of the OB receptor. Examples of such conformational characteristics include the conformation of the A major helix, the conformation of the D major helix, and the disulfide bond that maintains the geometrical relationship between the A and D major helices. Thus, amino acid substitutions that conserve the conformational characteristics of the molecule, for example, in the loop regions connecting the major helices, would produce conformational analogs to OB protein.

Peptides derived from the region of the OB protein from amino acid residues 106 to 140, as short as about 15 amino acids long, have been shown to be effective in mimicking the action of full-length recombinant OB protein (Grasso, P., et al., In vivo Effects of Leptin-Related Synthetic Peptides on Body Weight and Food Intake in Female *ob/ob* Mice: Localization of Leptin Activity to Domains Between Amino Acid Residues 106 - 140, Endocrinology **138**: 1413-1418 (1997)). As used herein, "OB-related peptides" refers to natural or synthetic peptides derived from the region of the OB protein from about amino acid residue 106 to about amino acid residue 140 and includes conservative amino acid residue substitutions.

The term "antibody" in its various grammatical forms is used herein to refer to immunoglobulin molecules and immunologically active portions

of immunoglobulin molecules, i.e., molecules that contain an antibody combining site or paratope. Exemplary antibody molecules are intact immunoglobulin molecules, substantially intact immunoglobulin molecules and those portions of an immunoglobulin molecule that contain the paratope, including those portions known in the art as Fab, Fab' and F(ab')<sub>2</sub>. An antibody composition of the present invention is characterized as containing antibody molecules that immunoreact with OB protein or portions thereof.

An antibody composition of the present invention is typically produced by immunizing a mammal with a inoculum of OB protein or some fragment of OB protein, alone or in combination with a suitable adjuvant such as Freund's adjuvant, and thereby induce in the mammal antibody molecules having the appropriate immunospecificity. The antibody molecules are then collected from the mammal and isolated to the extent desired by well known techniques such as, for example, immunoaffinity chromatography. The antibody composition so produced can be used, inter alia, in the diagnostic methods and systems of the present invention or in the preparation of therapeutic compositions of the present invention.

Monoclonal antibody compositions can also be used with the present invention. A monoclonal antibody composition contains, within detectable limits, only one species of antibody combining site capable of effectively binding to OB protein. Thus, a monoclonal antibody composition of the present invention typically displays a single binding affinity for OB protein even though it may contain antibodies capable of binding proteins other than OB protein. Preferred monoclonal antibodies are those that bind to portions of the OB protein that are required for activation of the OB receptor, such as the A helix, the D helix, or regions of OB protein that maintain the relative positions of the A and D helices that are required for the activation of the OB receptor. Monoclonal antibodies against human OB protein have been described and their preparation was discussed in (Tsuruo, Y. et. al., Horm. Metab. Res. 28: 753-755 (1996).

Monoclonal antibodies are also supplied commercially from vendors on a custom

order basis (e.g., Alpha Diagnostic International, Inc., San Antonio, TX). Purified polyclonal anti-OB antibodies are commercially available from several sources (R&D Systems, Minneapolis, MN; Research Diagnostics, Inc., Flanders, N.J.; Linco Research, Inc., St. Charles, MO; Affinity BioReagents, Inc.,  
5 Golden, CO).

Determination of OB levels with OB antibodies is performed by assay methods, including ELISA, radioimmunoassay (RIA), Western blot analysis, and the like, that are familiar to one of ordinary skill in the art. The determined OB protein levels are then compared to normal levels for the state of  
10 the patient, e.g., fasting, time of day, body mass index (BMI), aerobic conditioning, gender, etc. For example, the normal range found for lean males at 8 a.m. was  $12.0 \pm 4.4$  ng/ml (Sinha, M.K., et al., Nocturnal Rise of Leptin in Lean, Obese, and Non-Insulin-dependent Diabetes Mellitus Subjects, J. Clin. Invest. **97**: 1344-1347 (1996)). See, also Horn, R. et al., Radioimmunoassay for  
15 the detection of leptin in human serum, Exp. Clin. Endocrinol. Diabetes **104**: 454-458 (1996); McGregor, G.P., et al., Radioimmunological Measurement of Leptin in Plasma of Obese and Diabetic Human Subjects, Endocrinology **137**: 1501-1504 (1996). It has recently been found that OB protein is present in the circulation in both bound and free form, and that the ratio of the two forms is  
20 different in lean and obese subjects (Sinha, M.K., et al., Evidence of Free and Bound Leptin in Human Circulation. Studies in Lean and Obese Subjects and During Short-Term Fasting, J. Clin. Invest. **98**: 1277-1282 (1996)). The relation of free and bound forms to OB protein biological activity can be considered in the context of OB protein assays.

25 In an alternative embodiment, immunohistochemical assay of OB-R receptor numbers are performed on tissue biopsy materials using standard protocols. A preferred tissue biopsy is liver biopsy.

### Therapeutic Applications

Embodiments of the present invention, including methods of administering to a patient compositions comprising OB-R agonist ligands are useful in treating conditions in which it is desirable to regulate or modify energy metabolism during a systemic inflammatory response. Suitable OB-R agonist ligands include recombinant OB protein, peptide conformational analogs of human OB protein comprising conservative substitutions of amino acid residues and OB-related peptides. A preferred OB-R agonist ligand is recombinant human OB protein. A suitable dosage range for recombinant human OB protein is from about 1 microgram per kilogram body weight to about 50 micrograms per kilogram body weight. OB-related peptides are used in a dosage range from about 0.1 microgram per kilogram body weight to about 5 micrograms per kilogram body weight, adjusting the dosage to account for art-recognized differences in potency and solubility (Grasso, P. et al., (1997)).

In a related embodiment, compositions comprising at least one OB-R expression inducer are useful for treating obesity and conditions in which there is an insufficient number of OB receptors, in which low copy number of OB receptors is a limiting factor or in which there is "OB resistance," i.e., a reduced effect of associated with a particular plasma concentration of OB protein.

In general, the OB-R expression inducer is administered in an amount from about 0.003 to about 20 micrograms per kilogram body weight. Suitable OB-R expression inducers include therapeutic cytokines used in cancer therapy, such as IL-1 $\alpha$ , IL-1 $\beta$ , IL-6 and TNF- $\alpha$ . Suitable dosages and modes of administration are known in the art. For example, a suitable dosage ranges for IL-1 $\alpha$  is about 0.1 to about 6 micrograms/m<sup>2</sup>/day. A suitable dosage range for IL-1 $\beta$  is about 3 to about 200 nanograms/kg/day. A suitable dosage range for IL-6 is about 0.5 to about 20 micrograms/kg/day, with a preferred dosage range for IL-6 being about 1 to about 5 micrograms/kg/day. The therapeutic cytokines may be administered singly or in combination. The mode of administration may be intravenous infusion over an extended time period or a single intravenous or

subcutaneous injection. The daily dose may be administered as a single dose or divided into multiple dose given at intervals during the day.

In a further embodiment, to counteract the possible toxic side effects of OB-R expression inducers such as therapeutic cytokines, such substances are administered in a composition in combination with OB-R agonist ligands. Administration of such compositions is useful for conditions in which cytokines are normally administered for a therapeutic purpose such as tumor treatment, in order to provide effective protection by the OB-R agonist ligands from undesirable metabolic side effects. The up-regulation of the OB-R allows for the complete therapeutic effect mediated by OB-R agonist ligands such as OB protein. A suitable dosage range for recombinant human OB protein is from about 1 microgram per kilogram body weight to about 50 micrograms per kilogram body weight.

In an alternative embodiment, the present invention describes the administration of OB antisera, polyclonal or monoclonal, for treating conditions marked by increased OB and/or increased OB-R activity. Such conditions are various wasting conditions or syndromes associated with several disease states or syndromes, including anorexia, amenorrhea, cachexia, chronic inflammatory conditions, AIDS and AIDS-related conditions. A suitable dosage range for anti-OB protein antibodies is about 0.02 to about 15 milligrams / kg / day.

It has been found that OB protein is an important host defense factor against endotoxin stress. The protective effect of OB protein against endotoxin was not caused by suppressing the expression of major inflammatory mediators, since the mRNA levels of IL-1 $\alpha$ , IL-1 $\beta$ , TNF- $\alpha$ , and iNOS in lung and spleen were similar in all LPS-treated mice regardless of the experimental manipulations (Figure 16). A comparison of the four groups of mice revealed striking correlations among the OB protein available, the survival from endotoxin shock (Figures 10 and 11), the maintenance of body temperature (Figures 12 and 13), and the loss of body weight (Figures 14 and 15).



Anti-OB Ab-treated mice showed the least loss of body weight and had the most profound hypothermia even with a relatively low dose of LPS. Conversely, OB-treated mice receiving a high dose of LPS maintained a higher body temperature than those control mice that received less LPS. The OB-treated mice also had a greater weight loss than any reported in the literature (16% in the first 24 hours, compared with an average of 10% reported by other groups). The mice in these tests were age, sex and weight matched, fed the same diet, and, therefore, should have had very similar energy store. The different responses to endotoxemia described were likely due to differences in metabolic energy mobilization and dissipation, which, in turn, were attributed to the experimental manipulation of circulating OB protein levels.

When the level of circulating OB protein is varied, the energy mobilized to resist endotoxin challenge is correspondingly altered, and the outcome of the host response to endotoxin stress is affected. *ob/ob* mice, lacking OB protein due to a mutation in the *ob* gene, were very sensitive to LPS insult: a dose as low as 2  $\mu$ g per gram of body weight caused a rapid fall of body temperature and death.

The results also suggest the existence of two pathways of thermogenesis and thermostasis. Anti-OB Ab treatment per se did not cause hypothermia in normal mice, suggesting that the thermostasis under non-pathological conditions was largely OB protein-independent. However, when given LPS, the anti-OB Ab-treated mice developed profound hypothermia, indicating that the thermogenesis in response to endotoxemia had become OB protein dependent. A corollary of this model is that genetic defects affecting the OB/OB-R pathway will have a severe hypothermic response to endotoxin. Indeed, *db/db* mice which carry a mutation in the OB-R gene, responded to a low dose of LPS injection in a manner very similar to that seen in *ob/ob* mice (data not shown), despite their increased level of OB expression.

### Example 1: Induction of OB-R Expression by Administration of LPS

The injection of LPS and cytokines, substances that are associated with sepsis, septic shock or SIRS caused increases in the expression of the OB receptor in peripheral organs such as liver, but not in brain.

5 Intravenous injection of lipopolysaccharide (LPS), IL-1 $\beta$ , TNF- $\alpha$  and IL-6 to mice induced OB receptor expression in the liver and other peripheral organs, but not in the central nervous system (CNS). To investigate the functional significance of the increased OB-R expression, an anti-OB antiserum was used to neutralize endogenous OB protein in mice prior to an LPS injection.

10 The neutralization of OB protein led to profound hypothermia, insignificant loss of body weight, and death in mice in response to an otherwise nonlethal dose of LPS. Conversely, mice administered recombinant mouse OB protein became more resistant to LPS and survived an otherwise lethal dose. The OB protein-treated mice maintained a relatively high body temperature and displayed

15 a dramatic weight loss. These results suggest that OB protein may promote energy mobilization to compensate for the increased energy consumption in endotoxemia, and that the OB/OB-R pathway may play an important role in critical host responses to inflammatory stress.

### Methods:

20 In general, standard techniques or published modifications were used; see, generally, Sambrook, J., et al., Molecular Cloning A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory Press (1989). C57BL/6 mice, 5-8 weeks of age and 17-20 g of weight, were injected intravenously with either LPS (5  $\mu$ g per gram of body weight, List Biological Laboratory, Campbell, CA),

25 IL-1 $\beta$  (R&D Systems, Minneapolis, MN), IL-6 (2.5  $\mu$ g, Pharmingen, San Diego, CA), or TNF- $\alpha$  (a gift from Genentech, San Francisco, CA). Animals were sacrificed at 0, 4, 8 or 24 hours, or 2, 3 or 5 days after the injection.

Tissue from various organs, including brain, liver and kidney, was dissected and snap-frozen in liquid nitrogen. Total RNA was prepared from the

30 frozen tissues by a single-step method (Chomczynski, P. & Sacchi, N., Single-

Step Method of RNA Isolation by Acid Guanidinium Thiocyanate-Phenol-Chloroform Extraction, Analytical Biochemistry **162**: 156-159 (1987).

The RNase protection assays were carried out as previously described (Feng, L., et al., Alternative Splicing of the NC1 Domain of the Human  $\alpha 3(\text{IV})$  Collagen Gene J. Biol. Chem. **269**: 2342-2348 (1994); Xia, Y., et al., LPS-Induced MCP-1, IL-1 $\beta$ , and TNF- $\alpha$  mRNA Expression in Isolated Erythrocyte-Perfused Rat Kidney, Am. J. Physiol. **264**: F774-F780 (1993)). A ten microgram aliquot of total RNA pooled from three similarly treated mice was used for each sample in the RNase protection assay. The stored pooled samples were dissolved in 10  $\mu\text{l}$  of 80% formamide, 0.4 M NaCl, 1 mM EDTA, and 40 mM piperazine-N,N'-bis(2-ethanesulfonic acid), heated to 85 degrees Celsius for 5 minutes. Each ten microgram sample was then hybridized with about  $1 \times 10^5$  cpm (counts per minute) of the appropriate [ $^{32}\text{P}$ ]UTP-labeled antisense riboprobe at 55 degrees Celsius for at least 10 hours. The unhybridized RNA was then digested with 50 unit/ml RNase T1 (GIBCO/BRL, Gaithersburg, MD) and 24  $\mu\text{g}/\text{ml}$  RNase A at 30 degrees Celsius for one hour. The RNase was then digested with 625  $\mu\text{g}/\text{ml}$  proteinase K (Boehringer Mannheim, Indianapolis, IN) for 30 minutes at 37 degrees Celsius. After phenol-chloroform extraction and sodium-acetate-ethanol precipitation, the protected hybridized RNA was denatured and electrophoresed on a 10% polyacrylamide gel. The gels were transferred to 3M Whatman filter paper, dried and exposed to Kodak X-Omat film. The resulting autoradiograms were developed in a Kodak X-Omat processor were used only for qualitative screening.

Radioactivity due to hybridization of target sequences with  $^{32}\text{P}$ -labeled riboprobes was quantified by scanning the gels on an AMBIS radioanalytic scanning system (AMBIS Systems, San Diego, CA).

An OB-Rb cDNA probe (from base 2548 to base 2835 of OB-Rb, Gen-Bank™ Accession No. U46135) was subcloned from a full-length mouse OB-Rb cDNA. The full-length mouse cDNA for the OB-R long form (OB-Rb)

was cloned from a mouse hypothalamus cDNA library (Stratagene, La Jolla, CA), and the sequence was verified against that of U46135.

5 The full-length mouse cDNA for the OB-R short form (OB-Ra) was cloned from a mouse lung cDNA Library (Stratagene, La Jolla, CA). A 224 bp probe that included base 1250 to base 1474 (as indicated on the OB-Rb sequence) of OB-Ra was used for the RNase protection assay. This fragment, which comprises a sequence that is shared by all variants of OB-R, was used as a probe for the total level of OB-R (OBR<sub>(t)</sub>).

10 The expression of other forms of OB-R mRNA was analyzed using selective probes for the respective different forms of OB-R. The designated probes provided full protection to their corresponding OB-R forms and partial protection for other OB-R forms. A probe derived from L32 (33-126, Gen-Bank™ Accession No. XO6483), a housekeeping gene encoding ribosomal protein, was used as a control.

15 OB-Rc and OB-Re probes were cloned by reverse-transcription-PCR (RT-PCR) of total liver RNA from LPS-treated C57BL/6 mice. Protocols for RT-PCR are known in the art (for example, pages 15-13 - 15-15 of Ausubel, F.M., et al., Short Protocols in Molecular Biology, 2nd Edition, John Wiley and Sons, New York, (1992)).

20 One suitable protocol for RT-PCR is a modification of that previously described (Feng, L., et al., J. Biol. Chem. **269**: 2342-2348, 1994). The primers used in RT-PCR are listed in Table 1, below. Primer oligonucleotides were synthesized using an ABI model 380B synthesizer (Applied BioSystems, Foster City, Ca).

Table 1: PCR Primers

		Sequence	
	OB-Rc sense	5'-GCTATCGACAAGCAGCAGAAT-3'	(SEQ ID NO. 8)
5	OB-Rc antisense	5'-TGAACACAACAACATAAAGCCC-3'	(SEQ ID NO. 9)
	OB-Re sense	5'-TGTTATATCTGGTTATTATTGAATGG-3'	(SEQ ID NO. 10)
10	OB-Re antisense	5'-CATTAAATGATTTATTATCAGAATTGC-3'	(SEQ ID NO. 11)

First strand cDNA synthesis was performed using total liver RNA from LPS-treated C57BL/6 mice and murine leukemia virus reverse transcriptase with a random hexanucleotide primer. The 100  $\mu$ l reaction mixture contained standard enzyme buffer, 5  $\mu$ g of total RNA, 20 units of RNasin (RNase inhibitor), 500 pmol of hexanucleotide primer, 10 mM dithiothreitol, 1 mM of each dNTP, with 200 units of reverse transcriptase. Each reaction mixture was heated to 95 degrees Celsius for 10 minutes. PCR was then performed with separate aliquots of the reaction mixture with the appropriate primers for 35 cycles, using 60 degrees Celsius for annealing.

The cDNA segments used to generate riboprobes were excised by the appropriate restriction endonucleases and subcloned into the multiple cloning site of a standard transcription vector. Suitable transcription vectors include a vector chosen from the pGEM series (Promega, Madison, WI). Labelled single stranded riboprobes were synthesized using standard *in vitro* transcription protocols, either those provided by the manufacturer or other standard protocols (e.g. Ausubel, F.M., et al., pages 4-18 - 4-21) with the appropriate (e.g., SP6 or T7) bacteriophage RNA polymerase. The riboprobes contained regions corresponding to the vector polylinker in addition to the region corresponding to the target sequence, and thus were longer than the protected bands. The mouse ribosomal L32 gene, a constitutively expressed "housekeeping" gene, was used throughout the study as a control.

### Results:

When LPS was administered to C57BL/6 mice, a strong induction of total OB-R expression (OB-R<sub>0</sub>) was detected in a number of peripheral organs (Figure 1), but not in several areas of the central nervous system, such as the hypothalamus, that are known to express OB-R (compare Figure 1 and Figure 6). The increased expression of OB-R was most prominent in the liver, the major site of metabolic regulation. The increase of OB-R mRNA expression in the liver was LPS dose-dependent, and peaked between 24 and 48 hours post-LPS injection (Figure 1).

Unexpectedly, RNase protection assays using probes specific for alternatively spliced forms of OB-R mRNA revealed that the long form, OB-Rb, was also induced in the liver to a level comparable to that found in the *ob/ob* mouse hypothalamus and greater than that of the lean control mouse hypothalamus (Figure 2). However, the majority of hepatic OB-R were the OB-Ra, OB-Rc (Figure 3) and OB-Re (Figure 4) forms. OB-Rd expression in the liver was undetectable (data not shown).

In addition to LPS, OB-R expression was induced by the cytokines IL-6, IL-1 $\alpha$  and TNF- $\alpha$  (Figure 5). Contrary to a recent report (12), we found no detectable increase in OB expression in white adipose tissue in LPS-treated mice, but detected a distinct induction of OB mRNA expression in the adrenal gland (Figure 4). No OB mRNA expression was found in the brain, heart, lung, liver, kidney, spleen, muscle, stomach, duodenum, jejunum, ileum, or colon of LPS-treated mice (data not shown).

### Example 2: Production of Recombinant OB Protein

Recombinant OB protein was expressed in *E. coli* using a prokaryotic expression vector and extracted from inclusion bodies. Other vectors and host cells systems, including eukaryotic cells, are known in the art and also suitable for the expression of OB protein. See, generally, Ausubel, F.M., et al. Short Protocols in Molecular Biology, 2nd Ed., pages 16-1 to 16-89.

The coding region of mouse OB cDNA (65-619, Gen-Bank™ Accession No.U18812) was cloned by RT-PCR of total RNA from C57BL/6 white adipose tissue. The coding region was subcloned in expression vector, pETM1 (Feng, L., et al., *J. Biol. Chem.* 269: 2342-2348, 1994), to express a His-tagged recombinant mouse OB protein. The construction of pETM1 from the commercially available vector pET-11a (Novagen, Madison, WI) is illustrated on Figure 8.

After the expression of OB protein is induced, the bacteria were harvested and the inclusion bodies were extracted with a buffer containing 6M urea. The extract was loaded on a Ni-NTA affinity column (Qiagen, Chatsworth, CA) and the purification procedure was carried out as previously described (Feng, et al.(1994)). The protein was refolded on the column by adding refolding buffer containing 5 mM CaCl<sub>2</sub>/20 mM Tris/0.2 NaCl with an urea gradient of 4 M - 0.5 M at a rate of about 0.5 ml/minute. After refolding, the protein was eluted with 80 mM imidazole/5 mM CaCl<sub>2</sub>/20 mM Tris/0.2 NaCl/0.5 mM urea and then dialyzed against phosphate-buffered saline (PBS). Polyclonal antibodies was raised by immunizing a rabbit with the recombinant mouse OB and Freund's adjuvant using standard procedures. Antiserum was used in the following examples.

#### Example 3: Effects of Anti-OB Antibodies on Metabolism

Intravenous administration of antibodies directed against OB protein effectively opposes the effects of endogenous OB protein.

Recombinant mouse OB protein was produced in an *E. coli* expression system as described in Example 2, and was used to generate rabbit polyclonal anti-OB antibody. The antibody, when injected intravenously into mice, stimulated food intake, leading to rapid weight gain, and thus was effective in blocking OB protein function. The results are shown in Figure 9.

Female C57BL/6 mice, 6-8 weeks of age and 15-17 g of weight, were group housed four per cage and adapted to a 12:12 hour light: dark cycle (light from 6:00 to 18:00). Mice were given a daily intravenous injection of 0.2

ml anti-OB antiserum or preimmune rabbit sera ("vehicle") at 10 p.m., after their initial dark phase food intake. Their body weight was measured at 10 a.m. the next day.

5 The weight gain induced by anti-OB antiserum is illustrated in Figure 9. Data are expressed as mean  $\pm$  S.E.M. (N=8). While the weight of the control group remained essentially constant over the week, the anti-OB treated group showed a weight increase at the first weighing, which continued for the entire study period.

10 Example 4: Effects of Anti-OB Antibodies and Recombinant OB-Protein on Response to Endotoxic Shock

The fact that the OB-R variants induced in the liver were predominantly short forms raised the question of functional relevance of the hepatic OB-R expression. OB-Rb is the main form expressed in the hypothalamus, while the choroid plexus expresses only OB-Ra. That the  
15 mutation in *db/db* mice affects OB-Rb, but not OB-Ra, suggests that OB-Rb is crucial for regulating food intake and OB-Ra may act as an OB protein transporter. Accordingly, the prominent expression of OB-R in the liver could initiate intracellular signal transduction or, alternatively, mediate the clearance of OB protein. We found that administration of neutralizing anti-OB antibody (Ab)  
20 or OB protein to LPS-treated mice distinguished between the two alternatives.

Male C57BL/6 mice, 5-8 weeks of age and 17-21 g of body weight, were used for this study. For antisera treatment, mice were given an i.v. injection of 200  $\mu$ l rabbit antisera. LPS at a dose of 6  $\mu$ g per gram of body weight was then co-injected with a second dose of anti-OB antibody to the  
25 pretreated mice. LPS was dissolved in antisera at a concentration of 0.6 mg/ml and was injected intravenously 4 hours after the initial antisera treatment. Food was retrieved from mouse cages during the 4-hour pretreatment period to prevent any food intake differences resulting from anti-OB antiserum-induced hyperphagia, and was added back after LPS injection.



While this dose of LPS was not lethal to C57BL/6 mice treated with preimmune rabbit serum, all the mice in the anti-OB Ab-treated group died within 40 hours. Figure 10 illustrates the results from three groups of mice: those pretreated with anti-OB antiserum (anti-OB, N=16), preimmune rabbit sera control, N=16), or three other unrelated rabbit antisera ("Anti-X", N=3 for each antiserum). This LPS sensitizing effect was specific for anti-OB Ab, since mice treated similarly with three other unrelated antibodies ("Anti-X") all survived (Figure 10).

In comparison, mice treated with OB protein (5  $\mu$ g per gram of body weight mOB, N=16) were able to survive a higher dose of LPS (10  $\mu$ g per gram of body weight) that was fatal to the control group of mice receiving the vehicle alone (control, N=16). Mouse OB protein and LPS were prepared in saline at a concentration of 0.5 mg/ml and 1 mg/ml, respectively, and injected intravenously into the mice. A vehicle solution used for OB protein dialysis was injected into control mice. To eliminate any circadian effect, experiments at different days were all started at the same hours. Mice were examined at 4-hour intervals post LPS injection for the first 24 hours, and survival was monitored for 7 days following the LPS injection. The results are shown in Figure 11. The dose of LPS killed all the mice in the control group within 24 hours. However, in the experimental group, OB protein treatment conferred mice complete resistance to this dose of endotoxin. The OB-treated mice displayed noticeably less severe symptoms of endotoxemia, remaining alert and responsive to touch and other manipulation, and recovering quickly.

The effects of both OB protein and anti-OB antibodies on body temperature and body weight were monitored in the same groups of mice. Core body temperature measurements were made by insertion of a thermistor probe (Yellow Springs Instrument, Yellow Springs, Ohio) into the colon, 1.5 cm beyond the rectum. Body weight measurements were made on a portable digital balance (Ohaus, Florham Park, NJ).

The mice receiving anti-OB antibodies, which ultimately died, showed lower body temperature (Figure 12) and less weight loss (Figure 14) than the corresponding control group than survived. Conversely, the mice receiving OB-protein, and which survived the endotoxic shock, showed higher body  
5 temperature (Figure 13) and more weight loss (Figure 15) than the corresponding control group which succumbed.

While administration of both OB protein and anti-OB antibodies had significant effects on survival, body weight and body temperature, there was little effect on the expression of iNOS, IL-1 $\alpha$ , IL-1 $\beta$ , and TNF- $\alpha$  mRNAs in lung  
10 and spleen (Figure 16). Mice were treated as described in above (Figures 10-15).

RNase protection assays were performed as described in Example 1. Each sample was 5  $\mu$ g total RNA was used for each sample in the RNase protection assay. Riboprobes were produced as described in Example 1 based on the following cDNA fragments: IL-1 $\alpha$  (from base 172 to base 366, Accession No.  
15 X01450, SEQ ID NO. 3), IL-1 $\beta$  (from base 500 to base 671, Accession No. M15131, SEQ ID NO. 4), TNF- $\alpha$  (from base 428 to base 557, Accession No. M11731, SEQ ID NO. 5), mouse iNOS (from base 2404 to base 2698, Accession No. M92649, SEQ ID NO. 6), and L32 (from base 33 to base 126, Accession No. X064383, SEQ ID NO. 7).

20 Relatively little change in the pattern of expression of these markers was observed (Figure 16), suggesting that these the protective actions of OB proteins are direct and not indirect and mediated by these cytokines.

The foregoing is intended to be illustrative of the present invention, but not limiting. Numerous variations and modifications of the present invention  
25 may be effected without departing from the true spirit and scope of the invention.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- (i) APPLICANT: Feng, Lili  
Chen, Sizhong  
Xia, Yiyang
- (ii) TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC METHODS  
RELATED TO REGULATING ENERGY MOBILIZATION WITH OB PROTEIN  
AND OB ANTIBODIES
- (iii) NUMBER OF SEQUENCES: 11
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: Olson & Hierl, Ltd.
  - (B) STREET: 20 North Wacker Drive, 36th Floor
  - (C) CITY: Chicago
  - (D) STATE: IL
  - (E) COUNTRY: US
  - (F) ZIP: 60606
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Floppy disk
  - (B) COMPUTER: IBM PC compatible
  - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
  - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER:
  - (B) FILING DATE: 04-JUN-1997
  - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
  - (A) APPLICATION NUMBER: US 60/018,972
  - (B) FILING DATE: 04-JUN-1996
- (viii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: Olson, Arne M
  - (B) REGISTRATION NUMBER: 30,203
  - (C) REFERENCE/DOCKET NUMBER: TSRI540.1PCT
- (ix) TELECOMMUNICATION INFORMATION:
  - (A) TELEPHONE: 312-580-1180
  - (B) TELEFAX: 312-580-1189

## (2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 2793 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: double
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Mus musculus*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GGATCCCTGC	TCCAGCAGCT	GCAAGGTGCA	AGAAGAAGAA	GATCCCAGGG	AGGAAAATGT	60
GCTGGAGACC	CCTGTGTCGG	TTCCTGTGGC	TTTGGTCCTA	TCTGTCTTAT	GTTCAAGCAG	120
TGCCTATCCA	GAAAGTCCAG	GATGACACCA	AAACCCTCAT	CAAGACCATT	GTCACCAGGA	180
TCAATGACAT	TTCACACACG	CAGTCGGTAT	CCGCCAAGCA	GAGGGTCACT	GGCTTGGA	240
TCATTCCCTGG	GCTTCACCCC	ATTCTGAGTT	TGTCCAAGAT	GGACCAGACT	CTGGCAGTCT	300
ATCAACAGGT	CCTCACCAGC	CTGCCTTCCC	AAAATGTGCT	GCAGATAGCC	AATGACCTGG	360
AGAATCTCCG	AGACCTCCTC	CATCTGCTGG	CCTTCTCCAA	GAGCTGCTCC	CTGCCTCAGA	420
CCAGTGGCCT	GCAGAAGCCA	GAGAGCCTGG	ATGGCGTCCT	GGAAGCCTCA	CTCTACTCCA	480
CAGAGGTGGT	GGCTTTGAGC	AGGCTGCAGG	GCTCTCTGCA	GGACATTCTT	CAACAGTTGG	540
ATGTTAGCCC	TGAATGCTGA	AGTTTCAAAG	GCCACCAGGC	TCCAAGAAT	CATGTAGAGG	600
GAAGAAACCT	TGGCTTCCAG	GGGTCTTCAG	GAGAAGAGAG	CCATGTGCAC	ACATCCATCA	660
TTCATTTCTC	TCCCTCCTGT	AGACCACCCA	TCCAAAGGCA	TGACTCCACA	ATGCTTGACT	720
CAAGTTATCC	ACACAACTTC	ATGAGCACAA	GGAGGGGCCA	GCCTGCAGAG	GGGACTCTCA	780
CCTAGTTCTT	CAGCAAGTAG	AGATAAGAGC	CATCCCATCC	CCTCCATGTC	CCACCTGCTC	840
CGGGTACATG	TTCCTCCGTG	GGTACACGCT	TCGCTGCGGC	CCAGGAGAGG	TGAGGTAGGG	900
ATGGGTAGAG	CCTTTGGGCT	GTCTCAGAGT	CTTTGGGAGC	ACCGTGAAGG	CTGCATCCAC	960
ACACAGCTGG	AAACTCCCAA	GCAGCACACG	ATGGAAGCAC	TTATTTATTT	ATTCTGCATT	1020
CTATTTTGGA	TGGATCTGAA	GCAAGGCATC	AGCTTTTTC	GGCTTTGGGG	GTCAGCCAGG	1080
ATGAGGAAGG	CTCCTGGGGT	GCTGCTTTCA	ATCCTATTGA	TGGGTCTGCC	CGAGGCAAAC	1140
CTAATTTTTG	AGTGACTGGA	AGGAAGGTTG	GGATCTTCCA	AACAAGAGTC	TATGCAGGTA	1200
GCGCTCAAGA	TTGACCTCTG	GTGACTGGTT	TTGTTTCTAT	TGTGACTGAC	TCTATCCAAA	1260
CACGTTTGCA	GCGGCATTGC	CGGGAGCATA	GGCTAGGTTA	TTATCAAAAG	CAGATGAATT	1320
TTGTCAAGTG	TAATATGTAT	CTATGTGCAC	CTGAGGGTAG	AGGATGTGTT	AGAGGGAGGG	1380
TGAAGGATCC	GGAAGTGTTT	TCTGAATTAC	ATATGTGTGG	TAGGCTTTTC	TGAAAGGGTG	1440
AGGCATTTTC	TTACCTCTGT	GGCCACATAG	TGTGGCTTTG	TGAAAAGGAC	AAAGGAGTTG	1500
ACTCTTTCCG	GAACATTTGG	AGTGTACCAG	GCACCCTTGG	AGGGGCTAAA	GCTACAGGCC	1560
TTTTGTTGGC	ATATTGCTGA	GCTCAGGGAG	TGAGGGCCCC	ACATTTGAGA	CAGTGAGCCC	1620
CAAGAAAAGG	GTCCCTGGTG	TAGATCTCCA	AGGTTGTCCA	GGGTTGATCT	CACAATGCGT	1680

TTCTTAAGCA	GGTAGACGTT	TGCATGCCAA	TATGTGGTTC	TCATCTGATT	GGTTCATCCA	1740
AAGTAGAACC	CTGTCTCCCA	CCCATTCTGT	GGGGAGTTTT	GTTCCAGTGG	GAATGAGAAA	1800
TCACCTTAGCA	GATGGTCCTG	AGCCCTGGGC	CAGCACTGCT	GAGGAAGTGC	CAGGGCCCCA	1860
GGCCAGGCTG	CCAGAATTGC	CCTTCGGGCT	GGAGGATGAA	CAAAGGGGCT	TGGGTTTTTC	1920
CATCACCCCT	GCACCCTATG	TCACCATCAA	ACTGGGGGGC	AGATCAGTGA	GAGGACACTT	1980
GATGGAAAGC	AATACACTTT	AAGACTGAGC	ACAGTTTCGT	GCTCAGCTCT	GTCTGGTGCT	2040
GTGAGCTAGA	GAAGCTCACC	ACATACATAT	AAAAATCAGA	GGCTCATGTC	CCTGTGGTTA	2100
GACCCTACTC	GCGGCGGTGT	ACTCCACCAC	AGCAGCACCG	CACCGCTGGA	AGTACAGTGC	2160
TGTCTTCAAC	AGGTGTGAAA	GAACCTGAGC	TGAGGGTGAC	AGTGCCCAGG	GGAACCCTGC	2220
TTGCAGTCTA	TTGCATTTAC	ATACCGCATT	TCAGGGCACA	TTAGCATCCA	CTCCTATGGT	2280
AGCACACTGT	TGACAATAGG	ACAAGGGATA	GGGGTTGACT	ATCCCTTATC	CAAAATGCTT	2340
GGGACTAGAA	GAGTTTTTGA	TTTTAGAGTC	TTTTCAGGCA	TAGGTATATT	TGAGTATATA	2400
TAAAATGAGA	TATCTTGGGG	ATGGGGCCCA	AGTATAAACA	TGAAGTTCAT	TTATATTTCA	2460
TAATACCGTA	TAGACACTGC	TTGAAGTGTA	GTTTTATACA	GTGTTTTAAA	TAACGTTGTA	2520
TGCATGAAAG	ACGTTTTTTAC	AGCATGAACC	TGTCTACTCA	TGCCAGCACT	CAAAAACCTT	2580
GGGGTTTTTG	AGCAGTTTGG	ATCTTGGGTT	TTCTGTTAAG	AGATGGTTAG	CTTATACCTA	2640
AAACCATAAT	GGCAAACAGG	CTGCAGGACC	AGACTGGATC	CTCAGCCCTG	AAGTGTGCCC	2700
TTCCAGCCAG	GTCATACCCT	GTGGAGGTGA	GCGGGATCAG	GTTTTGTGGT	GCTAAGAGAG	2760
GAGTTGGAGG	TAGATTTTGG	AGGATCTGAG	GGC			2793

## (2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 3862 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: double
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
  - (A) ORGANISM: Mus musculus

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

GTCGACCCAC	GCGTCCGGAG	GAATCGTTCT	GCAAATCCAG	GTGTACACCT	CTGAAGAAAG	60
ATGATGTGTC	AGAAATTCTA	TGTGGTTTTG	TTACTACTGGG	AATTTCTTTA	TGTGATAGCT	120

GCACTTAACC TGGCATATCC AATCTCTCCC TGGAATTTA AGTTGTTTTG TGGACCACCG	180
AACACAACCG ATGACTCCTT TCTCTCACCT GCTGGAGCCC CAAACAATGC CTCGGCTTTG	240
AAGGGGGCTT CTGAAGCAAT TGTGAAGCT AAATTTAATT CAAGTGGTAT CTACGTTCTT	300
GAGTTATCCA AAACAGTCTT CCACTGTTGC TTTGGGAATG AGCAAGGTCA AAAGTCTCT	360
GCACTCACAG ACAACACTGA AGGGAAGACA CTGGCTTCAG TAGTGAAGGC TTCAGTTTTT	420
CGCCAGCTAG GTGTAAACTG GGACATAGAG TGCTGGATGA AAGGGGACTT GACATTATTC	480
ATCTGTCATA TGGAGCCATT ACCTAAGAAC CCCTTCAAGA ATTATGACTC TAAGGTCCAT	540
CTTTTATATG ATCTGCCTGA AGTCATAGAT GATTCGCCTC TGCCCCCACT GAAAGACAGC	600
TTTCAGACTG TCCAATGCAA CTGCAGTCTT CGGGGATGTG AATGTCATGT GCCGGTACCC	660
AGAGCCAAAC TCAACTACGC TCTTCTGATG TATTTGGAAA TCACATCTGC CGGTGTGAGT	720
TTTCAGTCAC CTCTGATGTC ACTGCAGCCC ATGCTTGTTG TGAAACCCGA TCCACCCTTA	780
GGTTTGCATA TGGAAGTCAC AGATGATGGT AATTTAAAGA TTTCTTGGGA CAGCCAAACA	840
ATGGCACCAT TTCCGCTTCA ATATCAGGTG AAATATTTAG AGAATTCTAC AATTGTAAGA	900
GAGGCTGCTG AAATTGTCTC AGCTACATCT CTGCTGGTAG ACAGTGTGCT TCCTGGATCT	960
TCATATGAGG TCCAGGTGAG GAGCAAGAGA CTGGATGGTT CAGGAGTCTG GAGTGAAGTG	1020
AGTTCACCTC AAGTCTTTAC CACACAAGAT GTTGTGTATT TTCCACCCAA AATTCTGACT	1080
AGTGTGGAT CGAATGCTTC TTTTCATTGC ATCTACAAAA ACGAAAACCA GATTATCTCC	1140
TCAAAACAGA TAGTTTGGTG GAGGAATCTA GCTGAGAAAA TCCCTGAGAT ACAGTACAGC	1200
ATTGTGAGTG ACCGAGTTAG CAAAGTTACC TTCTCCAACC TGAAAGCCAC CAGACCTCGA	1260
GGGAAGTTTA CCTATGACGC AGTGTAATGC TGCAATGAGC AGGCGTGCCA TCACCGCTAT	1320
GCTGAATTAT ACGTGATCGA TGTCAATATC AATATATCAT GTGAAACTGA CGGGTACTTA	1380
ACTAAAATGA CTTGCAGATG GTCACCCAGC ACAATCCAAT CACTAGTGGG AAGCACTGTG	1440
CAGCTGAGGT ATCACAGGCG CAGCCTGTAT TGTCTGATA GTCCATCTAT TCATCCTACG	1500
TCTGAGCCCA AAAACTGCGT CTTACAGAGA GACGGCTTTT ATGAATGTGT TTTCCAGCCA	1560
ATCTTTCTAT TATCTGGCTA TACAATGTGG ATCAGGATCA ACCATTCTTT AGGTTCACTT	1620
GAATCGCCAC CAACGTGTGT CCTTCCTGAC TCCGTAGTAA AACCCTACC TCCATCTAAC	1680
GTAAGAGCAG AGATTACTGT AAACACTGGA TTATTGAAAG TATCTTGGGA AAAGCCAGTC	1740
TTTCCGGAGA ATAACCTTCA ATTCCAGATT CGATATGGCT TAAGTGAAA AGAAATACAA	1800
TGGAAGACAC ATGAGGTATT CGATGCAAAG TCAAAGTCTG CCAGCCTGCT GGTGTCAGAC	1860
CTCTGTGCAG TCTATGTGGT CCAGGTTTCG TGCCGGCGGT TGGATGGACT AGGATATTGG	1920
AGTAATTGGA GCAGTCCAGC CTATACGCTT GTCATGGATG TAAAGTTCC TATGAGAGGG	1980

CCTGAATTTT	GGAGAAAAAT	GGATGGGGAC	GTTACTAAAA	AGGAGAGAAA	TGTCACCTTG	2040
CTTTGGAAGC	CCCTGACGAA	AAATGACTCA	CTGTGTAGTG	TGAGGAGGTA	CGTGGTGAAG	2100
CATCGTACTG	CCCACAATGG	GACGTGGTCA	GAAGATGTGG	GAAATCGGAC	CAATCTCACT	2160
TTCCTGTGGA	CAGAACCAGC	GCACACTGTT	ACAGTTCTGG	CTGTCAATTC	CCTCGGCGCT	2220
TCCCTTGTGA	ATTTTAACCT	TACCTTCTCA	TGGCCCATGA	GTAAAGTGAG	TGCTGTGGAG	2280
TCACTCAGTG	CTTATCCCCCT	GAGCAGCAGC	TGTGTCATCC	TTTCCTGGAC	ACTGTCACCT	2340
GATGATTATA	GTCTGTTATA	TCTGGTTATT	GAATGGAAGA	TCCTTAATGA	AGATGATGGA	2400
ATGAAGTGGC	TTAGAATTCC	CTCGAATGTT	AAAAAGTTTT	ATATCCACGA	TAATTTTATT	2460
CCCATCGAGA	AATATCAGTT	TAGTCTTTAC	CCAGTATTTA	TGGAAGGAGT	TGGAAAACCA	2520
AAGATAATTA	ATGGTTTCAC	CAAAGATGCT	ATCGACAAGC	AGCAGAATGA	CGCAGGGCTG	2580
TATGTCATTG	TACCCATAAT	TATTTCTCT	TGTGTCCTAC	TGCTCGGAAC	ACTGTTAATT	2640
TCACACCAGA	GAATGAAAAA	GTTGTTTTGG	GACGATGTTC	CAAACCCCAA	GAATTGTTCC	2700
TGGGCACAAG	GACTGAATTT	CCAAAAGCCT	GAAACATTTG	AGCATCTTTT	TACCAAGCAT	2760
GCAGAATCAG	TGATATTTGG	TCCTCTTCTT	CTGGAGCCTG	AACCCATTTT	AGAAGAAATC	2820
AGTGTCGATA	CAGCTTGGA	AAATAAAGAT	GAGATGGTCC	CAGCAGCTAT	GGTCTCCCTT	2880
CTTTTGACCA	CACCAGACCC	TGAAAGCAGT	TCTATTTGTA	TTAGTGACCA	GTGTAACAGT	2940
GCTAACTTCT	CTGGGTCTCA	GAGCACCCAG	GTAACCTGTG	AGGATGAGTG	TCAGAGACAA	3000
CCCTCAGTTA	AATATGCAAC	TCTGGTCAGC	AACGATAAAC	TAGTGGAAC	TGATGAAGAG	3060
CAAGGGTTTA	TCCATAGTCC	TGTCAGCAAC	TGCATCTCCA	GTAATCATTC	CCCACTGAGG	3120
CAGTCTTTCT	CTAGCAGCTC	CTGGGAGACA	GAGGCCCAGA	CATTTTTCCT	TTTATCAGAC	3180
CAGCAACCCA	CCATGATTTT	ACCACAACCT	TCATTCTCGG	GGTTGGATGA	GCTTTTGGA	3240
CTGGAGGGAA	GTTTTCTGA	AGAAAATCAC	AGGGAGAAGT	CTGTCTGTGA	TCTAGGAGTC	3300
ACCTCCGTCA	ACAGAAGAGA	GAGTGGTGTG	CTTTTGACTG	GTGAGGCAGG	AATCCTGTGC	3360
ACATTCCCAG	CCCAGTGTCT	GTTTCAGTGAC	ATCAGGATCC	TCCAGGAGAG	ATGCTCACAC	3420
TTTGTAGAAA	ATAATTTGAG	TTTAGGGACC	TCTGGTGAGA	ACTTTGTACC	TTACATGCCC	3480
CAATTTCAAA	CCTGTTCCAC	GCACAGTCAC	AAGATAATGG	AGAATAAGAT	GTGTGACTTA	3540
ACTGTGTAAT	CTCATCCAAG	AAGCCTCAAG	GTTCCATTCC	AGTAGAGCCT	GTCATGTATA	3600
ATGTGTTCTT	TTATTGTTGT	GGATGTGGGA	GACAAGTGTC	AGAATCTAGT	GTGAAAATGA	3660
TTGTTTCCAA	ACTAAGTGTG	TCTATTTTCT	CTCAGTAATA	CAATGAAACA	TATGAGGAAG	3720
CCCTCATTA	TCTAGTAATG	TAGATGGACT	CTTACTGAAT	ATATTCCCAA	GATACTTGGG	3780
GAAGTCTCCC	TAATTCTAGC	TAAAAATAAA	CCCAGGAATA	GAACTACTAA	ACACTGAATC	3840

TGGAAAAAAA AAAAAAAAAA AG

3862

## (2) INFORMATION FOR SEQ ID NO:3:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1974 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Mus musculus

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

AAGTCTCCAG GGCAGAGAGG GAGTCAACTC ATTGGCGCTT GAGTCGGCAA AGAAATCAAG	60
ATGGCCAAAG TTCCTGACTT GTTGAAGAC CTAAGAAGT GTTACAGTGA AAACGAAGAC	120
TACAGTTCTG CCATTGACCA TCTCTCTCTG AATCAGAAAT CCTTCTATGA TGCAAGCTAT	180
GGCTCACTTC ATGAGACTTG CACAGATCAG TTTGTATCTC TGAGAACCTC TGAAACGTCA	240
AAGATGTCCA ACTTCACCTT CAAGGAGAGC CGGGTGACAG TATCAGCAAC GTCAAGCAAC	300
GGGAAGATTC TGAAGAAGAG ACGGCTGAGT TTCAGTGAGA CCTTCACTGA AGATGACCTG	360
CAGTCCATAA CCCATGATCT GGAAGAGACC ATCCAACCCA GATCAGCACC TTACACCTAC	420
CAGAGTGATT TGAGATACAA ACTGATGAAG CTCGTCAGGC AGAAGTTTGT CATGAATGAT	480
TCCCTCAACC AAATATATA TCAGGATGTG GACAAACACT ATCTCAGCAC CACTTGGTTA	540
AATGACCTGC AACAGGAAGT AAAATTTGAC ATGTATGCCT ACTCGTCGGG AGGAGACGAC	600
TCTAAATATC CTGTTACTCT AAAAATCTCA GATTCACAAC TGTTTCGTGAG CGCTCAAGGA	660
GAAGACCAGC CCGTGTTGCT GAAGGAGTTG CCAGAAACAC CAAAACATCAT CACAGGTAGT	720
GAGACCGACC TCATTTTCTT CTGGAAAAGT ATCAACTCTA AGAACTACTT CACATCAGCT	780
GCTTATCCAG AGCTGTTTAT TGCCACCAA GAACAAAGTC GGGTGACCTT GGCACGGGGA	840
CTGCCCTCTA TGACAGACTT CCAGATATCA TAAAAGCAGC CTTATTTTCGG GAGTCTATTC	900
ACTTGGAAG TGCTGACAGT CTGTATGTAC CATGTACAGG AACCTTCCTC ACCCTGAGTC	960
ACTTGACAG CATGTGCTGA GTCTCTGTAA TTCTAAATGA ATGTTTACCC TCTTTGTAAG	1020
AGAAGAGCAA ACCCTAGTGG AGCCACCCCG ACATATGATA CTATCTGTTA TTTTAAAGAG	1080
TACCCTATAG TTTGCTCAGT ACTAATCATT TTAATTACTA TTCTGCATGG CATTCTTAGG	1140
AGGATCAAAA AGACTCTACA CATATTACAG ATGGGTAAAC AAAGGGATAA ACAAACCTGAA	1200



AAGCACACTC	AATGCATTTG	GAATATAAAT	TCACAGACCA	ATCTCACTGT	GCACCTTCGG	1260
CTTCAAAATG	CCAGTTGAGT	AGGATAAAGG	TATAAGAACT	TAATGCTGTC	ATTTTCAAAA	1320
GGAAGGGGAC	AATAGCTACA	TCTTTCCTAC	CTCAGTGGGT	TTTACTCCAG	TGAGATCATT	1380
TGGATGAAAT	CCTCCTGTAA	CAGACCTCAA	GAAGGAGACA	GACTGTTGAA	TGTTATTTTT	1440
AAGTTATTTT	ATATATGTAT	TTATAAATAT	ATTTATGATA	ATTATATTAT	TTATGGAACA	1500
TCCTTAAATC	CTCTGAGCTT	GACAGGCATC	CTCACAGCAG	GATTTTCTAG	GTGGTCAGTT	1560
AGATATAGTT	TCCTCTAGAG	CACCATGCTA	CAGACTTTAC	ACTTTTTCCA	CAGCCACGAA	1620
GCTCTCTGTA	CATTCCTGTA	CTTGGGAGCC	CTTTCATCAT	GATCTTAATC	TGTACTGTTT	1680
ACTTTGTTCA	TCTAAAATGA	TAATTGAGTC	AGTCTTTTTC	CCTCCCATCC	TTAAAGCTGT	1740
CTGGGTATTC	TTACATCATT	CAGTCTCACC	TGTAACCTAAC	ACCAACCATC	TAAAGATGGA	1800
AAGAGCTTAA	CTGTGACAAC	CACATCACTG	TTACCTGAAG	TTTCTTTTCT	AGAATGTAAT	1860
CAGTGTTTCC	CCTGGATTCC	AATTTTTTTT	TCAAACCACA	GTATCATGTA	ACTATCAACA	1920
ATAACAATCA	ACTCATTATT	ATTAATCATA	ATTAAATAAA	ACAAGTTTGA	GCTG	1974

## (2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 1339 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: double
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Mus musculus

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

TGCAGGGTTC	GAGGCCTAAT	AGGCTCATCT	GGGATCCTCT	CCAGCCAAGC	TTCCTTGTGC	60
AAGTGTCTGA	AGCAGCTATG	GCAACTGTTC	CTGAACTCAA	CTGTGAAATG	CCACCTTTTG	120
ACAGTGATGA	GAATGACCTG	TTCTTTGAAG	TTGACGGACC	CCAAAAGATG	AAGGGCTGCT	180
TCCAAACCTT	TGACCTGGGC	TGTCCAGATG	AGAGCATCCA	GCTTCAAATC	TCACAGCAGC	240
ACATCAACAA	GAGCTTCAGG	CAGGCAGTAT	CACTCATTGT	GGCTGTGGAG	AAGCTGTGGC	300
AGCTACCTGT	GTCTTTCCTG	TGGACCTTCC	AGGATGAGGA	CATGAGCACC	TTCTTTTCCT	360
TCATCTTTGA	AGAAGAGCCC	ATCCTCTGTG	ACTCATGGGA	TGATGATGAT	AACCTGCTGG	420
TGTGTGACGT	TCCCATTAGA	CAGCTGCACT	ACAGGCTCCG	AGATGAACAA	CAAAAAAGCC	480

TCGTGCTGTC GGACCCATAT GAGCTGAAAG CTCTCCACCT CAATGGACAG AATATCAACC	540
AACAAGTGAT ATTCTCCATG AGCTTTGTAC AAGGAGAACC AAGCAACGAC AAAATACCTG	600
TGGCCTTGGG CCTCAAAGGA AAGAATCTAT ACCTGTCTCTG TGTAATGAAA GACGGCACAC	660
CCACCCTGCA GCTGGAGAGT GTGGATCCCA AGCAATACCC AAAGAAGAAG ATGGAAAAGC	720
GGTTTGTCTT CAACAAGATA GAAGTCAAGA GCAAAGTGGA GTTTGAGTCT GCAGAGTTCC	780
CCAACTGGTA CATCAGCACC TCACAAGCAG AGCACAAGCC TGTCTTCCTG GGAAACAACA	840
GTGGTCAGGA CATAATTGAC TTCACCATGG AATCTGTGTC TTCCTAAAGT ATGGGCTGGA	900
CTGTTTCTAA TGCCTTCCCC AGGGCATGTG AAGGAGCTCC CTTGTCATGA ATGAGCAGAC	960
AGCTCAATCT CTAGGACACT CCTTAGTCCT CGGCCAAGAC AGGTCGCTCA GGGTCACAAG	1020
AAACCATGGC ACATTCTGTT CAAAGAGAGC CTGTGTTTTCC TCCTTGCCTC TGATGGGCAA	1080
CCACTTACCT ATTTATTTAT GTATTTATTG ATTGGTTGAT CTATTTAAGT TGATTCAAGG	1140
GGACATTAGG CAGCACTCTC TAGAACAGAA CCTAGCTGTC AACGTGTGGG GGATGAATTG	1200
GTCATAGCCT TGCACTTGAG GTCTTTCATT GAAGCTGAGA ATAAATAGGT TCCTATAATA	1260
TGGATGAGAA TTTTATGAA TGAAGCATT GCACATTGCT TTGATGAGTA TGAAATAAAT	1320
TTCATTAAAC AAACAAACA	1339

## (2) INFORMATION FOR SEQ ID NO:5:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1629 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Mus musculus

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

GCTGAGGGAC TAGCCAGGAG GGAGAACAGA AACTCCAGAA CATCCTGGAA ATAGCTCCCA	60
GAAAAGCAAG CAGCCAACCA GGCAGGTTCT GTCCCTTTCA CTCCTGGCC CAAGGCGCCA	120
CATCTCCCTC CAGAAAAGAC ACCATGAGCA CAGAAAGCAT GATCCGCGAC GTGGAAGTGG	180
CAGAAGAGGC ACTCCCCAA AAGATGGGGG GCTTCCAGAA CTCCAGGCGG TGCCTATGTC	240
TCAGCCTCTT CTCATTCTCTG CTTGTGGCAG GGGCCACCAC GCTCTTCTGT CTACTGAACT	300
TCGGGGTGAT CGGTCCCCAA AGGGATGAGA AGTTCCCAA TGGCCTCCCT CTCATCAGTT	360

CTATGGCCCA GACCCTCACA CTCAGATCAT CTTCTCAAAA TTCGAGTGAC AAGCCTGTAG	420
CCCACGTCGT AGCAAACCAC CAAGTGGAGG AGCAGCTGGA GTGGCTGAGC CAGCGCGCCA	480
ACGCCCTCCT GGCCAACGGC ATGGATCTCA AAGACAACCA ACTAGTGGTG CCAGCCGATG	540
GGTTGTACCT TGTCTACTCC CAGGTTCTCT TCAAGGGACA AGGCTGCCCC GACTACGTGC	600
TCCTCACCCA CACCGTCAGC CGATTTGCTA TCTCATACCA GGAGAAAGTC AACCTCCTCT	660
CTGCCGTCAA GAGCCCCTGC CCCAAGGACA CCCCTGAGGG GGCTGAGCTC AAACCCTGGT	720
ATGAGCCCAT ATACCTGGGA GGAGTCTTCC AGCTGGAGAA GGGGGACCAA CTCAGCGCTG	780
AGGTCAATCT GCCCAAGTAC TTAGACTTTG CGGAGTCCGG GCAGGTCTAC TTTGGAGTCA	840
TTGCTCTGTG AAGGGAATGG GTGTTTCATCC ATTCTCTACC CAGCCCCCAC TCTGACCCCT	900
TTACTCTGAC CCCTTTATTG TCTACTCCTC AGAGCCCCCA GTCTGTGTCC TTCTAACTTA	960
GAAAGGGGAT TATGGCTCAG AGTCCAACCTC TGTGCTCAGA GCTTTCAACA ACTACTCAGA	1020
AACACAAGAT GCTGGGACAG TGACCTGGAC TGTGGGCGCTC TCATGCACCA CCACCCACGG	1080
AATCGAGAAA GAGCTATCAA TCTGGAATTC ACTGGAGCCT CGAATGTCCA TTCCTGAGTT	1140
CTGCAAAGGG AGAGTGGTCA GGTTCCTCT GTCTCAGAAT GAGGCTGGAT AAGATCTCAG	1200
GCCTTCCTAC CTTCAGACCT TTCCAGACTC TTCCCTGAGG TGCAATGCAC AGCCTTCCTC	1260
ACAGAGCCAG CCCCCCTCTA TTTATATTTG CACTTATTAT TTATTATTTA TTTATTATTT	1320
ATTTATTTGC TTATGAATGT ATTTATTTGG AAGGCCGGGG TGTCCTGGAG GACCCAGTGT	1380
GGGAAGCTGT CTTCAGACAG ACATGTTTTT TGTGAAAACG GAGCTGAGCT GTCCCCACCT	1440
GGCCTCTCTA CTTGTTGCC TCCTCTTTTG CTTATGTTTA AAACAAAATA TTTATCTAAC	1500
CCAATTGTCT TAATAACGCT GATTGTTGTA CCAGGCTGTC GCTACATCAC TGAACCTCTG	1560
CTCCCCACGG GAGCCGTGAC TGTAATTGCC CTACGGGTCA TTGAGAGAAA TAAAGATCGC	1620
TTGGAAAAG	1629

## (2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 4110 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: double
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
  - (A) ORGANISM: Mus musculus

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

GAGACTCTGG CCCCACGGGA CACAGTGTCA CTGGTTTGAA ACTTCTCAGC CACCTTGGTG	60
AAGGGACTGA GCTGTTAGAG ACACTTCTGA GGCTCCTCAC GCTTGGGTCT TGTTCACTCC	120
ACGGAGTAGC CTAGTCAACT GCAAGAGAAC GGAGAACGTT GGATTTGGAG CAGAAGTGCA	180
AAGTCTCAGA CATGGCTTGC CCCTGGAAGT TTCTCTTCAA AGTCAAATCC TACCAAAGTG	240
ACCTGAAAGA GGAAAAGGAC ATTAACAACA ACGTGAAGAA AACCCTTGT GCTGTTCTCA	300
GCCCAACAAT ACAAGATGAC CTAAGAGTC ACCAAAATGG CTCCCCGCAG CTCCTCACTG	360
GGACAGCACA GAATGTTCCA GAATCCCTGG ACAAGCTGCA TGTGACATCG ACCCGTCCAC	420
AGTATGTGAG GATCAAAAAC TGGGGCAGTG GAGAGATTTT GCATGACACT CTTCAACCACA	480
AGGCCACATC GGATTTCACT TGCAAGTCCA AGTCTTGCTT GGGGTCCATC ATGAACCCCA	540
AGAGTTTGAC CAGAGGACCC AGAGACAAGC CTACCCCTCT GGAGGAGCTC CTGCCTCATG	600
CCATTGAGTT CATCAACCAG TATTATGGCT CCTTTAAAGA GGCAAAAATA GAGGAACATC	660
TGGCCAGGCT GGAAGCTGTA ACAAAGGAAA TAGAAACAAC AGGAACCTAC CAGCTCACTC	720
TGGATGAGCT CATCTTTGCC ACCAAGATGG CCTGGAGGAA TGTCCCTCGC TGCATCGGCA	780
GGATCCAGTG GTCCAACCTG CAGGTCTTTG ACGCTCGGAA CTGTAGCACA GCACAGGAAA	840
TGTTTCAGCA CATCTGCAGA CACATACTTT ATGCCACCAA CAATGGCAAC ATCAGGTCGG	900
CCATCACTGT GTTCCCCCAG CGGAGTGACG GCAAACATGA CTTCAGGCTC TGGAAATTCAC	960
AGCTCATCCG GTACGCTGGC TACCAGATGC CCGATGGCAC CATCAGAGGG GATGCTGCCA	1020
CCTTGGAGTT CACCCAGTTG TGCATCGACC TAGGCTGGAA GCCCCGCTAT GGCCGCTTTG	1080
ATGTGCTGCC TCTGGTCTTG CAAGCTGATG GTCAAGATCC AGAGGTCTTT GAAATCCCTC	1140
CTGATCTTGT GTTGAGGTG ACCATGGAGC ATCCCAAGTA CGAGTGGTTC CAGGAGCTCG	1200
GGTTGAAGTG GTATGCACTG CCTGCCGTGG CCAACATGCT ACTGGAGGTG GGTGGCCTCG	1260
AATTCCCAGC CTGCCCCTTC AATGGTTGGT ACATGGGCAC CGAGATTGGA GTTCGAGACT	1320
TCTGTGACAC ACAGCGCTAC AACATCCTGG AGGAAGTGGG CCGAAGGATG GGCCTGGAGA	1380
CCCACACACT GGCCTCCCTC TGGAAAGACC GGGCTGTCAC GGAGATCAAT GTGGCTGTGC	1440
TCCATAGTTT CCAGAAGCAG AATGTGACCA TCATGGACCA CCACACAGCC TCAGAGTCCT	1500
TCATGAAGCA CATGCAGAAT GAGTACCGG CCCGTGGAGG CTGCCCCGCA GACTGGATTT	1560
GGCTGGTCCC TCCAGTGTCT GGGAGCATCA CCCCTGTGTT CCACCAGGAG ATGTTGAACT	1620
ATGTCCTATC TCCATTCTAC TACTACCAGA TCGAGCCCTG GAAGACCCAC ATCTGGCAGA	1680
ATGAGAAGCT GAGGCCCAGG AGGAGAGAGA TCCGATTTAG AGTCTTGGTG AAAGTGGTGT	1740
TCTTTGCTTC CATGCTAATG CGAAAGGTCA TGGCTTCACG GGTCAGAGCC ACAGTCCTCT	1800

TTGCTACTGA	GACAGGGAAG	TCTGAAGCAC	TAGCCAGGGA	CCTGGCCACC	TTGTTCAGCT	1860
ACGCCTTCAA	CACCAAGGTT	GTCTGCATGG	ACCAGTATAA	GGCAAGCACC	TTGGAAGAGG	1920
AGCAACTACT	GCTGGTGGTG	ACAAGCACAT	TTGGGAATGG	AGACTGTCCC	AGCAATGGGC	1980
AGACTCTGAA	GAAATCTCTG	TTCATGCTTA	GAGAACTCAA	CCACACCTTC	AGGTATGCTG	2040
TGTTTGGCCT	TGGCTCCAGC	ATGTACCCTC	AGTTCTGCGC	CTTTGCTCAT	GACATCGACC	2100
AGAAGCTGTC	CCACCTGGGA	GCCTCTCAGC	TTGCCCCAAC	AGGAGAAGGG	GACGAACTCA	2160
GTGGGCAGGA	GGATGCCTTC	CGCAGCTGGG	CTGTACAAAC	CTTCCGGGCA	GCCTGTGAGA	2220
CCTTTGATGT	CCGAAGCAAA	CATCACATTC	AGATCCCGAA	ACGCTTCACT	TCCAATGCAA	2280
CATGGGAGCC	ACAGCAATAT	AGGCTCATCC	AGAGCCCGGA	GCCTTTAGAC	CTCAACAGAG	2340
CCCTCAGCAG	CATCCATGCA	AAGAACGTGT	TTACCATGAG	GCTGAAATCC	CAGCAGAATC	2400
TGCAGAGTGA	AAAGTCCAGC	CGCACCAACC	TCCTCGTTCA	GCTCACCTTC	GAGGGCAGCC	2460
GAGGGCCCAG	CTACCTGCCT	GGGGAACACC	TGGGGATCTT	CCCAGGCAAC	CAGACCGCCC	2520
TGGTGCAGGG	AATCTTGGAG	CGAGTTGTGG	ATTGTCTTAC	ACCACACCAA	ACTGTGTGCC	2580
TGGAGGTTCT	GGATGAGAGC	GGCAGCTACT	GGGTCAAAGA	CAAGAGGCTG	CCCCCTGCT	2640
CACTCAGCCA	AGCCCTCACC	TACTTCCTGG	ACATTACGAC	CCCTCCCACC	CAGCTGCAGC	2700
TCCACAAGCT	GGCTCGCTTT	GGCACGGACG	AGACGGATAG	GCAGAGATTG	GAGGCCTTGT	2760
GTCAGCCCTC	AGAGTACAAT	GACTGGAAGT	TCAGCAACAA	CCCCACGTTT	CTGGAGGTGC	2820
TTGAAGAGTT	CCCTTCCTTG	CATGTGCCCC	CTGCCTTCCT	GCTGTGCGAG	CTCCCTATCT	2880
TGAAGCCCCG	CTACTACTCC	ATCAGCTCCT	CCCAGGACCA	CACCCCTCG	GAGGTTCAAC	2940
TCACTGTGGC	CGTGGTCACC	TACCGCACCC	GAGATGGTCA	GGGTCCCCTG	CACCATGGTG	3000
TCTGCAGCAC	TTGGATCAGG	AACCTGAAGC	CCCAGGACCC	AGTGCCCTGC	TTTGTGCGAA	3060
GTGTCAGTGG	CTTCCAGCTC	CCTGAGGACC	CCTCCCAGCC	TTGCATCCTC	ATTGGGCCTG	3120
GTACGGGCAT	TGCTCCCTTC	CGAAGTTTCT	GGCAGCAGCG	GCTCCATGAC	TCCCAGCACA	3180
AAGGGCTCAA	AGGAGGCCGC	ATGAGCTTGG	TGTTTGGGTG	CCGGCACCCG	GAGGAGGACC	3240
ACCTCTATCA	GGAAGAAATG	CAGGAGATGG	TCCGCAAGAG	AGTGCTGTTC	CAGGTGCACA	3300
CAGGCTACTC	CCGGCTGCCC	GGCAAACCCA	AGGTCTACGT	TCAGGACATC	CTGCAAAAGC	3360
AGCTGGCCAA	TGAGGTACTC	AGCGTTCTCC	ACGGGGAGCA	GGGCCACCTC	TACATTTGCG	3420
GAGATGTGCG	CATGGCTCGG	GATGTGGCTA	CCACATTGAA	GAAGCTGGTG	GCCACCAAGC	3480
TGAACTTGAG	CGAGGAGCAG	GTGGAAGACT	ATTTCTTCCA	GCTCAAGAGC	CAGAAACGTT	3540
ATCATGAAGA	TATCTTCGGT	GCAGTCTTTT	CCTATGGGGC	AAAAAAGGGC	AGCGCCTTGG	3600
AGGAGCCCAA	AGCCACGAGG	CTCTGACAGC	CCAGAGTTCC	AGCTTCTGGC	ACTGAGTAAA	3660

GATAATGGTG AGGGGCTTGG GGAGACAGCG AAATGCAATC CCCCCAAGC CCCTCATGTC	3720
ATTCCCCCCT CCTCCACCCT ACCAAGTAGT ATTGTATTAT TGTGGACTAC TAAATCTCTC	3780
TCCTCTCCTC CCTCCCCTCT CTCCCTTTCC TCCCTTCTTC TCCACTCCCC AGCTCCCTCC	3840
TTCTCCTTCT CCTCCTTTGC CTCTCACTCT TCCTTGGAGC TGAGAGCAGA GAAAACTCA	3900
ACCTCCTGAC TGAAGCACTT TGGGTGACCA CCAGGAGGCA CCATGCCGCC GCTCTAATAC	3960
TTAGCTGCAC TATGTACAGA TATTTATACT TCATATTTAA GAAAACAGAT ACTTTTGTCT	4020
ACTCCCAATG ATGGCTTGGG CCTTTCCTGT ATAATTCCTT GATGAAAAAT ATTTATATAA	4080
AATACATTTT ATTTTAATCA AAAAAAAAAA	4110

## (2) INFORMATION FOR SEQ ID NO:7:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 465 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Rattus norvegicus

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

GGCATCATGG CTGCCCTTCG GCCTCTGGTG AAGCCCAAGA TCGTCAAAAA GAGGACCAAG	60
AAGTTCATCA GGCACCAGTC GGACCGATAT GTGAAAATTA AGCGAAACTG GCGGAAACCC	120
AGAGGCATCG ACAACAGGGT GCGGAGAAGA TTCAAGGGCC AGATCCTGAT GCCCAACATT	180
GGTTACGGGA GTAACAAGAA AACCAAGCAC ATGCTGCCTA GCGGCTTCCG GAAGTTTCTG	240
GTCCACAATG TCAAGGAGCT GGAAGTGCTG CTGATGTGCA ACAAATCTTA CTGTGCTGAG	300
ATTGCTCACA ATGTGTCCTC TAAGAACCGA AAAGCCATCG TAGAAAGAGC AGCACAGCTG	360
GCCATCAGAG TCACCAATCC CAACGCCAGG CTACGCAGCG AAGAGAATGA ATAGATGGCT	420
TGTGTGCCTG TTTTGTGTTC AAATAAAACC ACAAAAAGT CCAA	465

## (2) INFORMATION FOR SEQ ID NO:8:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
  - (A) ORGANISM: Mus musculus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:  
GCTATCGACA AGCAGCAGAA T

21

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 22 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
  - (A) ORGANISM: Mus musculus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:  
TGAACACAAC AACATAAAGC CC

22

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 26 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
  - (A) ORGANISM: Mus musculus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:  
TGTTATATCT GGTTATTATT GAATGG

26

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Mus musculus

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

CATTAAATGA TTTATTATCA GAATTGC

27



## WE CLAIM:

1. A method for treating a patient having a condition in which regulating energy metabolism during a systemic inflammatory response is desired, comprising administering a composition having a physiologically effective amount of at least one OB-R agonist ligand.

2. The method of claim 1 wherein the OB-R agonist ligand is.. recombinant human OB protein.

3. The method of claim 2 wherein the amount of recombinant human OB protein administered is from about 1 microgram per kilogram body weight to about 50 micrograms per kilogram body weight.

4. The method of claim 1 wherein the OB-R agonist ligand is a peptide conformational analog of human OB protein comprising conservative substitutions of amino acid residues.

5. The method of claim 1 wherein the OB-R agonist ligand is an OB-related peptide.

6. The method of claim 1 wherein the condition is sepsis.

7. The method of claim 1 wherein the condition is systemic inflammatory response syndrome.

8. A composition for treating a patient having a condition in which regulating energy metabolism during a systemic inflammatory response is desired, comprising a physiologically effective amount of at least one OB-R agonist ligand.

9. The composition of claim 8 wherein the OB-R agonist ligand is recombinant human OB protein.

10. The composition of claim 9 wherein the amount of recombinant human OB protein per dose is from about 1 microgram per kilogram body weight to about 50 micrograms per kilogram body weight.

11. The composition of claim 8 wherein the OB-R agonist ligand is a peptide conformational analog of human OB protein comprising conservative substitutions of amino acid residues.

12. The composition of claim 8 wherein the OB-R agonist  
5 ligand is an OB-related peptide.

13. The composition of claim 8 wherein the condition is sepsis.

14. The composition of claim 8 wherein the condition is systemic inflammatory response syndrome.

15. A composition for the amelioration of the toxicity of  
10 therapeutic cytokines comprising a physiologically effective amount of an OB-R agonist ligand.

16. The composition of claim 15 wherein the OB-R agonist ligand is recombinant human OB protein.

17. The composition of claim 15 wherein the amount of  
15 recombinant human OB protein per dose is 1 microgram per kilogram body weight to about 50 micrograms per kilogram body weight.

18. A method for the treatment of a patient having obesity comprising the steps of:

20 administering at least one OB-R expression inducer; and  
administering a physiologically effective amount of an OB-R agonist ligand.

19. The method of claim 18 wherein the OB-R expression inducer is a compound chosen from the group consisting of LPS, IL-1 $\alpha$ , IL-1 $\beta$ , TNF- $\alpha$  and IL-6.

20. The method of claim 18 wherein the OB-R expression  
25 inducer and the OB-R agonist ligand are administered at a different times.

21. The method of claim 18 wherein the OB-R expression inducer is administered in an amount from about 0.003 to about 20 micrograms per kilogram body weight.

22. The method of claim 18 wherein the OB-R agonist ligand is administered in an amount from about 1 microgram per kilogram body weight to about 50 micrograms per kilogram body weight.

23. The method of claim 18 wherein the OB-R agonist ligand is recombinant human OB protein.

24. The method of claim 23 wherein the recombinant human OB protein is administered in an amount from about 1 micrograms per kilogram body weight to about 50 micrograms per kilogram body weight.

25. The method of claim 18 wherein the OB-R expression inducer is IL-6.

26. The method of claim 25 wherein IL-6 is administered in an amount from about 0.5 to about 20 micrograms per kilogram body weight.

27. A method for the treatment of a patient having a condition characterized by OB resistance, comprising the steps of:

administering IL-6 in an amount from about 0.5 to about 20 micrograms per kilogram body weight; and

administering recombinant human OB protein in an amount from about 1 microgram per kilogram body weight to about 50 micrograms per kilogram body weight.

28. A composition suitable for the treatment of obesity comprising:

at least one therapeutic cytokine capable of increasing the expression of the OB receptor;

a physiologically effective amount of an OB-R agonist ligand; and a pharmaceutically acceptable excipient.

29. The composition of claim 28 wherein the therapeutic cytokine capable of increasing the expression of the OB receptor and the OB-R agonist ligand are packaged separately.

30. The composition of claim 28 wherein the therapeutic cytokine is about 0.5 to about 20 micrograms per kilogram body weight IL-6.

31. The composition of claim 29 wherein the OB-R agonist ligand is administered in a dose of about 1 micrograms per kilogram body weight to about 50 micrograms per kilogram body weight recombinant human OB protein.

5                   32. An assay kit for a disease marker in a sample for a systemic inflammatory response in a patient comprising:

an antibody capable of binding to OB protein; and

a detection means for determining the amount of the antibody bound to OB protein.

10                   33. A method for assaying a disease marker for an inflammatory response in a patient comprising:

mixing a portion of the sample with an antibody capable of binding to OB protein; and

detecting the amount of antibody bound to OB protein.

15                   34. A composition suitable for the treatment of anorexia, cachexia or other wasting condition comprising a physiologically effective amount of antibody capable of binding OB protein.

20                   35. The method for the treatment of anorexia, cachexia or other wasting condition comprising administering a physiologically effective amount of antibody capable of binding OB protein in an amount from about 0.02 to about 15 milligrams per kilogram body weight per day.




FIG. 1



2 / 12




FIG. 2




FIG. 3





3/12



FIG. 4



4 / 12




FIG. 5






FIG. 6



6 / 12




FIG. 7





7 / 12




FIG. 8



8 / 12




FIG. 9



9 / 12




FIG. 10




FIG. 11



10 / 12




FIG. 12




FIG. 13





11 / 12




FIG. 14




FIG. 15






FIG. 16



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/09684

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) : A61K 38/00, 45/05, 38/19, 39/395

US CL : 514/2, 8, 12; 424/85.1, 158.1, 145.1

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/2, 8, 12; 424/85.1, 158.1, 145.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE, DIALOG, MEDLINE

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96/05309 A3 (THE ROCKEFELLER UNIVERSITY) 22 February 1996, (22-02-96), see the claims.	1-35
X, P	WO 96/35787 A1 (CHIRON CORPORATION) 14 November 1996 (14-11-96), see entire document, and claims.	1-35
X	PELLELYMOUNTER et al. Effects of the obese Gene Product on Body Weight Regulation in ob/ob Mice. Science, 28 July 1995, Vol. 269, see pages 540-543.	8-17, 18-26
X	HALAAS et al. Weight-Reducing Effects on the Plasma Protein Encoded by the obese Gene. Science, 28 July 1995, Vol. 269, see pages 543-547.	8-17, 18-26

☒ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means		
*P* document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

02 SEPTEMBER 1997

Date of mailing of the international search report

23 SEP 1997

 Name and mailing address of the ISA/US  
 Commissioner of Patents and Trademarks  
 Box PCT  
 Washington, D.C. 20231

Facsimile No. (703) 305-3230

 Authorized officer  
 GARNETTE D. DRAPER

Telephone No. (703) 308-0196

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US97/09684

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT


Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GRUNFELD et al. Endotoxin and Cytokines Induce Expression of Leptin, the ob Gene Product, in Hamsters. Journal of Clinical Investigations. Clin. Invest. May 1996, Vol. 97, see pages 2152-2157.	1-35
X, P	SARRAF et al. Multiple Cytokines and Acute Inflammation Raise Mouse Leptin Levels: Potential Role in Inflammatory Anorexia. Journal of Experimental Medicine. 06 January 1997, Vol. 185, Number 1, see pages 171-175.	1-35
X, P	ROUBENOFF et al. TNF-alpha and leptin in adjuvant arthritis (AA): Implications for inflammatory cachexia. Arthritis & Rheumatism, September 1996, Vol. 39, No. 9 (supplement), see Abstract No. 302, page s77.	1-35
A, P	GAINSFORD et al. Leptin can induce proliferation, differentiation, and functional activation of hemopoietic cells. Proc. Natl. Acad. Sci. December 1996, Vol. 93, see pages 14564-14568.	1-35
A, P	BENNETT et al. A role for leptin and its cognate receptor in hematopoiesis. Current Biology, 1996, Vol. 6, No. 9, see pages 1178-1180.	1-35

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)



Applicant's or agent's file reference TSRI 540.1 PCT	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US97/09684	International filing date (day/month/year) 04 JUNE 1997	Priority date (day/month/year) 04 JUNE 1996
International Patent Classification (IPC) or national classification and IPC IPC(6): A61K 38/00, 45/05, 38/19, 39/395 and US Cl.: 514/2, 8, 12; 424/85.1, 158.1, 145.1		
Applicant THE SCRIPPS RESEARCH INSTITUTE		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 4 sheets.

☐ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority. (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of — sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of report with regard to novelty, inventive step or industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand  30 DECEMBER 1997	Date of completion of this report  17 AUGUST 1998
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer  GARNETTE D. DRAPER Telephone No. (703) 308-0196





# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US97/09684

## I. Basis of the report

1. This report has been drawn on the basis of *(Substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments):*

☒ the international application as originally filed.

☒ the description, pages 1-38, as originally filed.

pages NONE, filed with the demand.

pages NONE, filed with the letter of \_\_\_\_\_.

pages \_\_\_\_\_, filed with the letter of \_\_\_\_\_.

☒ the claims, Nos. 1-35, as originally filed.

Nos. NONE, as amended under Article 19.

Nos. NONE, filed with the demand.

Nos. NONE, filed with the letter of \_\_\_\_\_.

Nos. \_\_\_\_\_, filed with the letter of \_\_\_\_\_.

☒ the drawings, sheets/fig 1-16, as originally filed.

sheets/fig NONE, filed with the demand.

sheets/fig NONE, filed with the letter of \_\_\_\_\_.

sheets/fig \_\_\_\_\_, filed with the letter of \_\_\_\_\_.

2. The amendments have resulted in the cancellation of:

☒ the description, pages NONE.

☒ the claims, Nos. NONE.

☒ the drawings, sheets/fig NONE.

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the ~~Supplemental Box~~ Additional observations below (Rule 70.2(c)).

4. Additional observations, if necessary:

NONE



## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US97/09684

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement****1. STATEMENT**

Novelty (N)	Claims <u>1-7, 18-27</u>	YES
	Claims <u>8-17, 28-35</u>	NO
Inventive Step (IS)	Claims <u>1-7, 18-27</u>	YES
	Claims <u>8-17, 28-35</u>	NO
Industrial Applicability (IA)	Claims <u>1-35</u>	YES
	Claims <u>NONE</u>	NO

**2. CITATIONS AND EXPLANATIONS**

Claims 8-17 lack novelty under PCT Article 33(2) as being anticipated by, or in the alternative lack an inventive step under PCT Article 33(3) as being obvious over The Rockefeller University ('309), Grunfeld et al, Pelleymounter et al or Halaas et al.

The claims are directed to compositions of the Ob protein or an Ob agonist ligand, wherein the claims recited several intended uses for the composition such as regulating energy metabolism during a systemic inflammatory response, or for ameliorating the toxicity of cytokines. Each of the prior art disclose composition of the Ob protein or related protein that are agonist, but the protein is disclosed for use in a different method from those of the claims. The prior art anticipate or render obvious the claims for a composition of the Ob protein irrespective of statements of intended for the composition. Furthermore, a composition per se is not distinct even if it is used for a different purpose or in a different method. Therefore, the burden is on the applicants to prove that the prior art composition does not possess the properties for methods of treatment consistent with the claims.

Claims 32-35 lack novelty under PCT Article 33(2) as being anticipated by, or in the alternative lack an inventive step under PCT Article 33(3) as being obvious The Rockefeller University ('309).

In addition to the above teachings, Friedman et al also disclose antibodies to the ob protein and teach that these antibodies can be used in diagnostic methods to detect for disorders associated with the Ob protein. Thus, the prior art appears to meet the claim limitation, irrespective of the fact that the language used to define the invention differs, and irrespective of statements of intended use for the antibody composition. Also taught is that the antibodies can be used to antagonist the undesired effect of the leptin, therefore to use the antibodies to treat low weight disorders is also anticipated or obvious from such teachings.

Claims 28-31 lack novelty under PCT Article 33(2) as being (Continued on Supplemental Sheet.)



## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US97/09684

**Supplemental Box**

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

Sheet 10

**V. 2. REASONED STATEMENTS - CITATIONS AND EXPLANATIONS (Continued):**

anticipated by, or in the alternative lack an inventive step under PCT Article 33(3) as being obvious Grunfeld et al.

Similar to the above, these claims are directed to a composition of the Ob protein and a cytokine, and wherein the claims recite specific statements of intended use for the composition. Grunfeld et al teach that endotoxin and cytokines induce the expression of leptin/ob in response to infection, and with this discovery, they provide compositions of the Ob protein and cytokines such as TNF, IL-1, IL-6, IL-8 and IFN. The prior art anticipate or render obvious the claims for a composition of the Ob protein and a cytokine irrespective of statements of intended for the composition. Furthermore, the composition per se is not distinct even if it is used for a different purpose or in a different method. Therefore, the burden is on the applicants to prove that the prior art composition does not possess the properties for methods of treatment consistent with the claims.

Claims 1-7, 18-31 lack an inventive step under PCT Article 33(2) as being obvious Grunfeld et al.

The disclosure of Grunfeld et al has been set forth above. Since the prior art teach that endotoxin such as LPS and cytokines induce expression of the Ob protein in response to infection. In view of the well known fact that many infections are associated with or are accompanied by inflammations, at the time of the invention it would have been obvious to use the ob protein alone or in conjunction with the endotoxin or a cytokine to regulate energy metabolism during inflammation that are associated with the ob protein.

Claims 1-35 the criteria set out in PCT Article 33(4); and claims 1-7 and 18-27 meet the criteria set out in PCT Article 33(2) because the prior art does not expressly teach the use of an Ob-R inducer with a cytokine and the Ob/leptin to treat obesity as claimed.

## NEW CITATIONS

NONE



## PATENT COOPERATION TREATY

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

United States Patent and Trademark  
Office  
(Box PCT)  
Crystal Plaza 2  
Washington, DC 20231  
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 16 February 1998 (16.02.98)	
International application No. PCT/US97/09684	Applicant's or agent's file reference TSRI 540.1 PCT
International filing date (day/month/year) 04 June 1997 (04.06.97)	Priority date (day/month/year) 04 June 1996 (04.06.96)
Applicant FENG, Lili et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

30 December 1997 (30.12.97)

☐ in a notice effecting later election filed with the International Bureau on:2. The election ☒ was☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland  Facsimile No.: (41-22) 740.14.35	Authorized officer  J. Leitao  Telephone No.: (41-22) 338.83.38
---	---





# PATENT COOPERATION TREATY

*jb*

PCT

## NOTIFICATION OF THE RECORDING OF A CHANGE

(PCT Rule 92bis.1 and  
Administrative Instructions, Section 422)

From the INTERNATIONAL BUREAU

To:

CEPURITIS, Talivaldis  
Olson & Hierl, Ltd.  
36th floor  
20 North Wacker Drive  
Chicago, IL 60606  
ETATS-UNIS D'AMERIQUE

Date of mailing (day/month/year) 20 February 1998 (20.02.98)	<b>IMPORTANT NOTIFICATION</b>
Applicant's or agent's file reference TSRI 540.1 PCT	
International application No. PCT/US97/09684	International filing date (day/month/year) 04 June 1997 (04.06.97)

1. The following indications appeared on record concerning:

☒ the applicant ☒ the inventor ☐ the agent ☐ the common representative

Name and Address

CHEN, Sizhong  
7896 Camino Kiosco  
San Diego, CA 92122  
United States of America

State of Nationality

CN

State of Residence

US

Telephone No.

Facsimile No.

Teleprinter No.

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☐ the person ☒ the name ☐ the address ☐ the nationality ☐ the residence

Name and Address

CHEN, Shizhong

State of Nationality

CN

State of Residence

US

Telephone No.

Facsimile No.

Teleprinter No.

3. Further observations, if necessary:

4. A copy of this notification has been sent to:

☒ the receiving Office ☐ the designated Offices concerned  
☐ the International Searching Authority ☒ the elected Offices concerned  
☒ the International Preliminary Examining Authority ☐ other:

The International Bureau of WIPO  
34, chemin des Colombettes  
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

Aino Metcalfe

Telephone No.: (41-22) 338.83.38



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/09684

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) : A61K 38/00, 45/05, 38/19, 39/395

US CL : 514/2, 8, 12; 424/85.1, 158.1, 145.1

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/2, 8, 12; 424/85.1, 158.1, 145.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE, DIALOG, MEDLINE

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96/05309 A3 (THE ROCKEFELLER UNIVERSITY) 22 February 1996, (22-02-96), see the claims.	1-35
X, P	WO 96/35787 A1 (CHIRON CORPORATION) 14 November 1996 (14-11-96), see entire document, and claims.	1-35
X	PELLELYMOUNTER et al. Effects of the obese Gene Product on Body Weight Regulation in ob/ob Mice. Science, 28 July 1995, Vol. 269, see pages 540-543.	8-17, 18-26
X	HALAAS et al. Weight-Reducing Effects on the Plasma Protein Encoded by the obese Gene. Science, 28 July 1995, Vol. 269, see pages 543-547.	8-17, 18-26

☒ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

02 SEPTEMBER 1997

Date of mailing of the international search report

23 SEP 1997

 Name and mailing address of the ISA/US  
 Commissioner of Patents and Trademarks  
 Box PCT  
 Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

GARNETTE D. DRAPER

Telephone No. (703) 308-0196



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US97/09684

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GRUNFELD et al. Endotoxin and Cytokines Induce Expression of Leptin, the ob Gene Product, in Hamsters. Journal of Clinical Investigations. Clin. Invest. May 1996, Vol. 97, see pages 2152-2157.	1-35
X, P	SARRAF et al. Multiple Cytokines and Acute Inflammation Raise Mouse Leptin Levels: Potential Role in Inflammatory Anorexia. Journal of Experimental Medicine. 06 January 1997, Vol. 185, Number 1, see pages 171-175.	1-35
X, P	ROUBENOFF et al. TNF-alpha and leptin in adjuvant arthritis (AA): Implications for inflammatory cachexia. Arthritis & Rheumatism, September 1996, Vol. 39, No. 9 (supplement), see Abstract No. 302, page s77.	1-35
A, P	GAINSFORD et al. Leptin can induce proliferation, differentiation, and functional activation of hemopoietic cells. Proc. Natl. Acad. Sci. December 1996, Vol. 93, see pages 14564-14568.	1-35
A, P	BENNETT et al. A role for leptin and its cognate receptor in hematopoiesis. Current Biology, 1996, Vol. 6, No. 9, see pages 1178-1180.	1-35

